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Abstract of Thesis 
 
Changes in Tissue-Specific Fatty Acid Composition of the Freshwater Alewife (Alosa 
pseudoharengus) in Response to Temperature 
 
 
A balance between fluidity and rigidity of cell membranes is essential for proper 
cell membrane function.   Ectotherms are known to alter the composition of the cell 
membrane to counter the increased order (when challenged with decreasing temperatures) 
or disorder (when challenged with increasing temperatures) that results from changes in 
environmental temperature.  One mechanism by which this can be accomplished is the 
alteration of the fatty acid composition of affected cellular membranes.  In this study, 
tissue-specific fatty acid composition in the alewife (Alosa pseudoharengus) was 
examined in response to both warm and cold temperature challenges administered over 
an approximate one month period.  Gill, muscle, and liver tissues were analyzed prior to 
the start of the temperature challenge (initial), following the temperature challenges 
(survivors), and on those fish that did not survive the temperature challenges 
(mortalities).  Significant differences were found between fatty acid composition of initial 
fish and survivors for membrane-incorporated fatty acids (polar) and for stored fatty acids 
(neutral).   In the cold challenge, gill tissues exhibited significant remodeling in 
membrane fatty acids (polar), including decreases in palmitic acid and saturated fatty 
acids and increases in highly unsaturated fatty acids.  In the warm challenge, significant 
increases in saturated fatty acids were observed in polar lipids of muscle and liver tissue.  
Notably, a large increase in palmitic acid (C16:0) was observed in response to increased 
temperatures.   Fatty acid profiles of fish that died during the cold challenge exhibited 
significantly higher levels of C16:0 in muscle tissues when compared to survivors.  The 
observed changes in membrane (polar) fatty acids would be expected to promote 
appropriate membrane fluidity in response to temperature.  Results of this study suggest 
that freshwater alewives respond to temperature challenges in accordance with what 
would be predicted by homeoviscous adaptation, although the pattern and extent of 
changes in response to temperature differed greatly among the tested tissues.   
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Abbreviations and Shorthand Notation 
ARA Arachidonic acid (C20:4n6)¹ 
DHA Docosahexanenoic acid (C22:6n3) 
EPA Eicosapentaenoic acid (C20:5n3) 
HUFA Highly unsaturated fatty acids 
MUFA Monounsaturated fatty acids 
n3 Omega-3 series fatty acids 
n6 Omega-6 series fatty acids 
PUFA Polyunsaturated fatty acids 
SAFA Saturated fatty acids 
¹ The shorthand notation used in the text, tables, and figures below indicates the 
following; Carbon chain length (C20 in this example), the number of double bonds 
in the carbon chain (4 in this example), and the position of the first double bond 
counting from the methyl end of the fatty acid  (n6 in this example).    
 
 
INTRODUCTION 
 
Many organisms are known to address thermodynamic changes in membrane 
fluidity by altering the molecular composition of the biomembrane, a physiological 
response known as homeoviscous adaptation.  Homeoviscous adaptation is common in 
ectotherms, and we know of several mechanisms by which organisms can modify the cell 
membrane in response to changing temperatures.   
 One approach is to alter membrane cholesterol incorporation.  Cholesterol 
interacts with the hydrophobic fatty acid tails of phospholipids and thereby increases the 
rigidity of the cell membrane (Alberts et al. 2002).  Increased incorporation of cholesterol 
is known to occur in response to increased environmental temperatures, whereas reduced 
incorporation occurs as temperatures decrease (Robertson and Hazel 1995).  It is 
important to note that the thickening effect of cholesterol is actually reversed at 
temperatures near zero Celsius.  As temperatures approach zero, cholesterol molecules 
contained in the phospholipid bilayer, instead of promoting thickening, disrupt bonding 
and can inhibit phase transitions (Alberts et al. 2002).  However, with regard to changes 
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in cholesterol incorporation in response to ambient temperature, cholesterol incorporation 
increases in response to increasing temperature within the range of temperatures normally 
experienced by most ectotherms. 
 Another mechanism by which homeoviscous adaptation can occur is molecular 
species remodeling, which involves an adjustment of fatty acid position/pairing in 
existing membrane phospholipids (see image below).  In this response, total fatty acid 
composition (or signature) remains unchanged; modification of membrane fluidity is 
achieved by altering the pairing or assortment of fatty acids, and may even be further 
modified by the chemical character of the polar head group to which they are bound.  The 
reason for the change in membrane fluidity despite the identical molecular makeup of the 
membrane is that certain fatty acids, when associated with particular polar head groups, 
are more fluid than others.   In response to a cold challenge, the fatty acid/polar head 
group combinations may undergo modification to favor a greater number of those 
combinations that contribute to fluidity.  Molecular species remodeling has been 
observed in rainbow trout (Hazel and Landrey 1988) and carp (Fodor et al. 1995) in 
response to decreased temperatures.    
 
A third means of adjusting biomembrane fluidity is to alter incorporation of the 
various common phospholipid polar head groups.  Increases in phosphatidylinositol and 
phosphatidlyethanolamine (both have a destabilizing effect on the biomembrane) and 
decreases in phosphatidylcholine (stabilizing effect) have been observed in response to 
decreasing temperatures (Greene and Selivonchick 1987, Henderson and Tocher 1987).   
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 One of the more commonly employed mechanisms of membrane fluidity 
adaptation is a change in the degree of saturation of phospholipid-bound fatty acids.  
Specifically, during cold acclimation the relative abundance of polyunsaturated (carbon 
chain containing more than one double bond) and highly unsaturated fatty acids (carbon 
chain containing four or more double bonds) increases as the abundance of saturated 
(carbon chain containing no double bonds) fatty acids decreases (Henderson and Tocher 
1987, Snyder and Hennessy 2003).  This response is not only common among fish 
species (Hazel and Williams, 1990), but is observed in microorganisms, fungi, plants, and 
invertebrates (Hazel 1995).  
My research is principally aimed towards changes in fatty acid composition as 
they pertain to predicted effects on membrane fluidity.  With respect to the organism of 
interest in this research effort, the alewife, a possible failure to effectively modify 
membranes in response to temperature is of interest for several reasons.  First, of the 
several mechanisms by which cell membranes can be modified to respond to changes in 
environmental temperatures, changes in the fatty acid composition in response to 
temperature is not only a common approach but has been demonstrated in alewives with 
analysis of whole body fatty acid profiles (Snyder and Hennessy, 2003).   
  Secondly, the increase in the degree of unsaturation of acyl chains in cell 
membranes in response to decreased temperatures is in part accomplished by increased 
incorporation of long chain, n3 polyunsaturated fatty acids.  The ability to incorporate 
higher amounts of these fatty acids in membranes is largely dependent on diet.  Several 
physiologically important long chain, n3 polyunsaturated fatty acids (DHA, EPA, ARA) 
are considered essential fatty acids for fish due to inability of any known fish species to 
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synthesize them from shorter chain (18:3n3) fatty acids (Sargent et al. 2002).  [As 
described in the terminology table above, the shorthand notation for fatty acids indicates 
the length of the fatty acid carbon chain (18 in this example), the number of double bonds 
contained in the fatty acid (3 in this example), and the position of the first double bond 
counting from the methyl end of the fatty acid (n3 in this example).] Should these EFA’s 
not be readily available in diet, the deficiency, which has been demonstrated to adversely 
affect numerous metabolic processes in fish (Roberts 2002, Sargent et al. 2002), would 
not be addressable by modification of shorter chain unsaturated fatty acids. 
 Lastly, and strongly associated with the point above, is that alewives are primarily 
anadromous and as such have evolved with a diet rich in PUFA’s.  However, freshwater 
populations of alewives that do not have the dietary availability of n3 polyunsaturated 
fatty acids of their anadromous relatives may be more susceptible to temperature change 
due to the decreased dietary availability of EFA’s.  
 
Storage lipids 
 In addition to the fatty acid composition of membranes, fatty acids primarily 
stored as triacylglycerols are also of interest. Triacylglycerols are stored in a variety of 
tissues including muscle, liver, and mesenteries.   Triacylglycerols serve as a major 
energy reservoir in a variety of animals, and provide approximately five times the energy 
provided by an equal weight of glycogen (Berg et al. 2002).  As a primary energy storage 
molecule, triacylglycerol levels increase when food is abundant and decrease when food 
is scarce.  These lipid stores are of critical importance to fish health as they are necessary 
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for overwinter survival, successful reproductive performance and development, and 
adequate response to environmental stress (Adams 1999).    
Though fatty acids stored as triacylglycerols do not directly impact membrane 
function, availability of fatty acids as triacylglycerols is important during periods of food 
shortage or starvation.  As triacylglycerol stores are depleted, mobilization of membrane 
associated fatty acids occurs (Tocher and Sargent 2003).   The use of structural lipids 
(phospholipids) for energy production when food is scarce may cause changes in 
membrane composition away from the optimal state.  The use of membrane fatty acids in 
response to low stored fatty acid reserves appears to be a contributor to the compromised 
osmoregulation observed in lipid deprived fish species (Adams 1999).  Consequently, 
membrane and stored fatty acids are intimately tied. 
 Stored fatty acids may also respond to temperature change to support and promote 
membrane change should modification in membranes be occurring.  Stored fatty acids are 
a reservoir of energy, but may also serve to store physiologically important fatty acids for 
use as structural components when needed (as phospholipids).  This would be particularly 
critical for an organism for which the necessary fatty acids are not readily available 
through the diet or cannot be synthesized endogenously. 
 Addressing changes in the fatty acid profiles of storage lipids when analyzing 
lipid response to temperature change is becoming increasingly important.  Though 
homeoviscous adaption theory was originally based on the response of membrane lipids, 
there is evidence that suggests homeoviscous adaptation applies to stored lipids as well.  
Stored lipids undergo physical property changes in response to low temperatures just as 
phospholipids do (by increased acyl chain bonding/association).  This effect can cause 
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triacylglycerols to solidify to a point that they are not suitable for lipase activity.  As 
such, they may become unsuitable as an energy source (Kostal and Simek 1998).  Similar 
to the response that is observed in membranes challenged with decreasing temperatures, 
increased unsaturation of the involved fatty acids helps alleviate the temperature induced 
cellular stress.    Therefore, maintenance of fluidity may be just as critical to stored lipids 
as to those lipids contained  in the cell membranes (Van Dooremalen et al. 2010). 
 
Temperature Acclimation 
The importance of fatty acid compositional changes in response to decreased 
temperatures has been extensively studied.  Salmon from different latitudes show a 
pattern of elevated highly unsaturated fatty acid DHA (C22:6n3) levels with decreasing 
temperatures, suggesting an important role for DHA in temperature acclimation (Olsen 
1999).   Similarly, DHA levels increased in plasma phospholipids of cold acclimated 
trout (Wallert and Babin 1994).  In addition to studies that examined fatty acid 
compositional changes in cold challenged fish, other studies in which dietary levels of 
PUFA were modified also demonstrate the importance of fatty acid modification to 
survivability.  Fish fed higher dietary levels of PUFA demonstrated higher cold tolerance 
(Craig et al. 1995, Kelly and Kohler 1999).   Furthermore, a study performed with 
alewives (Alosa pseudoharengus) indicated higher levels of membrane saturated fatty 
acids and lower levels of DHA in whole body extracts of cold challenged fish that were 
not able to survive a cold challenge (Snyder and Hennessey 2003). 
Relative to cold acclimation, our understanding of warm acclimation as it pertains 
to changes in lipid dynamics is not as extensive.  The effects of high temperature on 
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nutritional requirements and fatty acid signatures are poorly documented (Person Le-
Ruyet et al. 2004).  In a study using sea bass, warm acclimated fish held at either of two 
temperatures (22° and 29° C) showed a greater influence of temperature on membrane 
lipid than storage lipid.  Furthermore, the group maintained at the higher temperature 
(29°C) demonstrated lower levels of HUFA.  Both observations are in accordance with 
predictions based on homeoviscous adaptation theory, i.e., increased saturation in 
response to decreasing temperatures and decreased saturation in response to increasing 
temperatures (Person-Le Ruyet 2004). 
Fish can adapt relatively quickly to higher temperatures, often in less than 24 
hours; conversely, adaptation to lower temperatures is a slower process, and requires up 
to 20 days in some species (Doudoroff 1942, Brett 1944).  The rate at which acclimation 
to warmer temperatures occurs suggests that this response may be of less importance to 
an organism’s survival than cold acclimation.  However, study of the response to warmer 
temperatures is of value as it pertains to investigation of homeoviscous adaptation:  
response in fatty acid composition, particularly in the membranes, would be expected to 
behave in opposition to changes observed for cold challenged fish (Hazel and Williams 
1990).     
 
Tissue-Specific Fatty Acid Composition 
Different species of fish employ different strategies for fat deposition and 
mobilization, and the location and availability of these stores have been shown to affect 
survival in response to temperature change (Kelly and Kohler 1999).   Similarly, tissue-
specific differences in fatty acid composition are common in fishes due to the many 
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physiological processes in which fatty acids are involved.   Lower levels of DHA 
(C22:6n3), n3 fatty acids,  low n3/n6 ratios and elevated levels of ARA (C20:4n6) have 
been observed in gill membrane lipids when compared to other tissues (Fountoulaki et al. 
2003, Skalli et al. 2006).  Lower levels of C18:2n6 and EPA (C20:5n3) were observed in 
liver storage lipids when compared to gill and muscle tissues of European Sea bass 
(Skalli et al. 2006).   Fatty acid signatures of tissues, and any responses exhibited in 
tissue fatty acid composition due to temperature change, have the potential to vary for 
different tissues due to the many functions fatty acids serve.  Where a decrease in DHA 
might be predicted for both gill and liver tissue in response to increasing temperatures, 
such a change may not occur for reasons other than the predicted need to modify 
membrane fluidity (e.g. DHA requirement as a precursor for docasenoids in gill tissue, or 
increased preservation of a scarce essential fatty acid in liver neutral lipids).   
 
Alewives (Alosa pseudoharengus) in the Great Lakes 
The species of fish used in this research is the alewife, which inhabits many 
northeastern U.S. lakes (including all of the Laurentian Great Lakes and the New York 
State Finger Lakes).  Alewives are an important source of food for salmon and trout 
(Stewart and Ibarra 1991), and as such changes in alewife populations are predicted to 
affect the population size and health of these predatory game species.  Population 
dynamics of freshwater alewives remain poorly understood, and of particular concern, 
this species is subject to periodic mass mortalities.  One of the most notable of these 
events occurred in 1967, when an alewife fish kill of an estimated 300 million pounds 
occurred in Lake Michigan (Brown 1972).  The unpredictability and size of alewife mass 
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mortalities are consequently of great interest due to their potential impact on the yield of 
game fish stocking efforts.     
 Several possible causes for these mortalities have been explored.   Included in 
these are shortages in food supply, failure to adequately osmoregulate, failure to extract 
iodine, and combinations of these potential causes (Colby 1973).  However, studies of 
these mechanisms as contributors to alewife die-offs have in many cases been 
inconclusive and sometimes contradictory.  One example of such a contradiction was 
reported by O’Gorman and Schneider (O’Gorman and Schneider 1986), where alewives 
in poor condition prior to the winter season did not suffer unexpectedly large mortalities.  
Another example involves a study of the Lake Michigan mortality in 1967 in which it 
was noted that many of the dead alewives collected were in robust condition (Brown 
1968).  Despite efforts to date, the underlying physiological reasons for the mass-
mortalities remain poorly understood and the predictability of die-offs is inadequate for 
modeling freshwater alewife populations. 
 Another physiological mechanism which has been considered as a factor in 
temperature acclimation in alewives is maintenance of appropriate biomembrane fluidity.  
As discussed above, with changes in temperature the interactions among membrane-
bound phospholipids change (with respect to fatty acids as well as polar head groups).  
Changes in membrane fluidity are known to affect several cellular functions, including 
the activity of membrane bound enzymes, cell division, and channel function; changes in 
channel function in particular may lead to osmoregulatory difficulties, which have been 
reported for alewives subjected to low temperatures (Stanley and Colby 1971).  As mass 
mortalities often coincide with colder than average winters (Colby 1973, O’Gorman and 
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Schneider 1986) and low water temperatures are believed to adversely alewife growth 
and survival (Brown 1972, Colby 1973), a connection between changes in biomembrane 
fluidity and the health of freshwater alewife populations is evident.  A temperature-
induced loss of biomembrane fluidity might be significant enough to have a deleterious 
effect on an organism’s health, and a failure to compensate for these changes may result 
in decreased survival and the occurrence of large mortality events. 
 
The purpose of this study is to identify temperature-induced changes that occur in 
fatty acid signatures in each of three tissues (gill, muscle, liver) of freshwater alewives.  
Assessment of fatty acid signature changes, by comparing difference in both individual 
fatty acids and in fatty acid classes, may provide additional evidence of homeoviscous 
adaptation in this species as well as a more complete view of the role of fatty acids in the 
physiology of fishes in general in response to temperature change.     
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MATERIALS AND METHODS 
 
Overview of the experimental design 
 In this laboratory-based experiment, alewives were maintained at a constant 
temperature (15 °C) and fed a lipid-rich diet of frozen Mysis (a small freshwater shrimp)  
for 9 weeks.  Immediately following the acclimation period, two groups (N=25 for each 
group) of fish were subjected to a 4-5 week increasing temperature challenge, and two 
groups (N=25) were subjected to an approximately 30-day decreasing temperature 
challenge.  Temperature challenges were executed by changing temperature 0.5° C per 
day (increasing or decreasing), intended to be reflective of what might be expected in 
seasonal temperature shifts. This rate of temperature change also afforded the fish the 
opportunity to undergo membrane modification in response to the stress.   
Fatty acid composition of gill, liver, and muscle tissues were determined for fish 
samples taken prior to the temperature challenge (initial), fish that died during the trial 
(mortalities), and fish that survived the trial (survivors).  Polar (membrane-incorporated) 
and neutral (triaclyglyceride) fatty acid fractions were analyzed to allow for independent 
observation of changes that occur within biomembranes and stored fatty acids, 
respectively.  Comparison of initial and survivor samples allowed for determination of 
temperature (warm vs. cold) and tissue-specific modification of fatty acid composition.  
Analysis of warm and cold temperature mortalities were used to determine if these fish 
failed to modify fatty acid composition in the same manner observed in their respective 
survivor group.   
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Laboratory Temperature Challenge 
 Approximately 400 adult alewives were procured from Waneta Lake in the Finger 
Lakes Region of central New York, USA and were transported to the Buffalo State 
College Aquatic Research Laboratory for this study.   Individuals selected for use in the 
temperature challenge were similarly sized and weighed approximately 20 grams each.  
Selected individuals were distributed among four 760-liter circular tanks to provide a 
final density of 50 fish per tank.  Experimental tanks initially shared a common 
recirculating water supply and biofiltration system equipped with a mixed media filter 
and carbon filter.  Tank temperature was regulated using two in-line 1.5 horsepower 
chilling units.  Water contained 1% sodium chloride to minimize osmotic stress.   
During the conditioning stage of the study, tank temperature was maintained at 
15.0 ± 0.5°C for 9 weeks.  During this conditioning phase, fish received feedings of 
frozen Mysis twice daily.  Mysis was used as it is a natural high quality food source with 
a high lipid content, and it is rich in essential fatty acids EPA (C20:5n3)  and DHA 
(C22:6n3).  Thawed Mysis were provided in a daily ration constituting approximately 2-
3% of total alewife mass (number of fish x approximate wet body fish weight).  Mysis 
were procured from Piscine Energetics Inc, British Columbia, Canada.   
 An Aquanode monitoring system (Aquadyne, San Diego, CA) was used to 
continuously monitor water temperature, pH, and dissolved oxygen concentrations.  A 12 
L:12 D photoperiod was used for the duration of the experiment.  At the culmination of 
the nine week acclimation period, five fish were removed from each of the tanks and 
were euthanized with Ethyl 3-aminobenzoate methanesulfonate (MS-222) at 275 mg/L.  
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These fish were placed in plastic bags, fully immersed in water, and sealed prior to 
storage.  Samples were frozen and stored  at -80°C for analysis at a later date.  Length 
(cm) and weight (g) of these Initial Fish were recorded.  
 The alewives were then subdivided into four groups, each in its own separate tank 
and consisting of 25 fish.   Two tanks were subjected to an identical warm (increasing) 
temperature challenge, and the remaining two tanks were subjected to a cold (decreasing) 
temperature challenge.  In-line electric heaters were used to gradually increase the water 
temperature (0.5°C / day) of the warm challenge tanks from the initial temperature 
(15°C) to approximately 34°C over 39 days.  The cold challenge tanks were set to 
gradually decrease in temperature (0.5°C / day) from the initial 15°C to approximately 
1°C over 31 days.  The duration of the temperature challenges was based on the 
occurrence of mortality:  challenges were continued until individual mortalities numbers 
were adequate for analysis.  Following completion of the temperature challenges, all 
surviving fish were euthanized with MS-222 at 275 mg/L. Fish were placed in plastic 
bags, immersed in water, and were frozen and stored at -80°C as described above for 
Initial Fish.  Photoperiod and feeding schedule during the temperature challenges were 
consistent with those used in the conditioning period.  Alewives were fed daily during the 
temperature challenges; however, the feeding schedule was modified towards the end of 
the temperature challenges to account for declining feeding rates.   
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Sampling  
 At each daily feeding, tanks were examined for mortalities (deceased fish).  
Mortalities were removed from the tanks upon observation, measured (cm length) and 
weighed (g).  Carcasses were sealed in plastic bags, labeled (treatment, tank, and date) 
and stored frozen in water as describe above (-80°C) for subsequent analysis of fatty acid 
signatures.  
 At the culmination of the temperature treatments (~30 days from start of the 
temperature challenge), all surviving fish were sacrificed with a lethal dose of MS-222.  
All fish were measured, weighed, stored and processed as described above for the initial 
and mortality samples.  A summary of the design of the temperature challenges and 
overall survivorship during the experiment is provided in Table 1. 
 
Determination of Fatty Acid Signatures   
 Determination of fatty acid signatures is a three step process, and each of these is 
described in greater detail in the sections below.  For detailed descriptions of analytical 
protocols, reference Appendixes A, B, and C.  In short, tissues were removed from 
collected fish, after which fatty acids bound to phospholipids and triglycerides were 
extracted.  Extracted fatty acids were separated into polar (phospholipids) and neutral 
(triglycerides) fractions to allow independent analysis.  These products were then 
derivitized, a process which essentially frees the fatty acids from the glycerol backbone 
and facilitates detection.  Fatty acid derivatives were then analyzed using gas 
chromatography.  
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General Laboratory Procedures and Sample Handling  
 Tissue samples were kept under nitrogen and sealed with Teflon-lined caps to 
minimize oxidation of fatty acids.  Solvents used in volumes in excess of 1 ml were 
supplemented with the addition of 2,6-Di-tert-butyl-4-methylphenol (BHT, Sigma CAS 
128-37-0) added at 10mg/L to inhibit oxidation of samples.    Samples were spun in a 
centrifuge for 10 minutes to separate tissue from solvent, or aqueous phase from organic 
phase.   All sample/solvent transfers were performed in glass.   Reusable glassware was 
washed thoroughly, rinsed in methanol, and dried completely before re-use to prevent 
sample-to-sample contamination.   
 
Sample Selection and Preparation 
 A minimum of three samples were prepared for each of five sampling points.  
Sampling points included initial fish, warm survivors, cold survivors, warm mortalities, 
and cold mortalities.  Individual samples consisted of two fish (composite sampling) 
from which each of three tissues were removed; gills, liver, and muscle.  Composite 
samples were used to ensure that enough tissue was available for reproducible and 
accurate fatty acid analysis.  Prior to the start of the experiment, mortality samples were 
to be selected such that the sampling dates for both the warm and cold mortalities were 
similar for comparative purposes.  The majority of the mortalities occurred during the end 
phase of both warm and cold temperature challenges and made selection of temporally 
comparable mortality samples possible.  Furthermore, mortalities occurred for both the 
warm and cold temperature challenge in numbers large enough to allow for the 
preparation of composite samples.   
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Tissue collection 
 Ice was removed from frozen fish samples by immersion in lukewarm water.  
Following removal of ice, fish were set aside to thaw at room temperature (~ 30 minutes), 
after which tissue samples were excised and weighed.  All sample weights were recorded 
as wet weight (mg). 
 Gill Samples:  Following removal of the operculum, gill structures were excised 
from the fish and set on a dissection tray to isolate the gill tissues from the surrounding 
structure (see Appendix A).  Scissors were used to collect as much of the gill tissue 
(avoiding gill rakers and supporting structure) as the sample affords.  Excised gill tissue 
was weighed (wet weight) on a Mettler digital analytical balance and recorded.  Weights 
of gill tissue were recorded separately for each of the two composite fish and summed to 
provide a maximum sample weight.  Tissue collection from the composite was adjusted 
by removing sample from the greater of the two tissue yields so that contribution of each 
tissue to the total sample would be approximately 50%. 
 Liver Samples:  A cut was made along the ventral side of the fish from the anal fin 
to the operculum.  Another cut was then made from the anal fin to the lateral line, after 
which the cut moved laterally to the dorsal-most portion of the operculum.  Tissue 
(muscle/ribs) was pulled back with a pair of forceps to expose the liver.  This method 
causes minimal liver tissue disruption, facilitating a clean collection of the tissue even 
when the integrity of the liver is compromised.  From each of the two composite fish, 
approximately 150 mg of tissue were removed for a total of approximately 300 mg.  As 
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with the gill samples, tissue collections were adjusted so that the collection from each 
fish contributed approximately 50% of the total sample weight. 
 Muscle Samples:  Skin was removed from the fish, starting at the lateral line and 
moving upwards towards the dorsal fin.  Using a paper towel, fat and other subcutaneous 
material were gently abraded from the exposed muscle.  Using a scalpel, a small wedge 
of muscle tissue was excised from the dorsal portion of the fish.  Approximately 150 mg 
of tissue was collected from each of the composites to provide a 300 mg sample.   
 As mentioned above, collections of the three tissues were intended to obtain 
approximately 300 mg samples.  However, in cases where sample availability was below 
300 mg due to a low body weight or poor tissue integrity of one or both fish used for the 
composite, smaller samples in the 150 mg - 200 mg range were used and are more than 
adequate as the method employed has been successfully validated for samples as small as 
20 mg (Herbes and Allen 1983).  If a fish had degraded or was of questionable quality, 
the questionable sample was discarded and replaced with another from its group.  For all 
three tissue types, poor quality samples were identified by low tissue integrity/firmness.   
 
Fatty Acid Extraction    
The extraction procedure used was similar to a lipid microquantitation procedure 
reported by Herbes and Allen (1983), which produces consistent lipid recoveries with 
relatively small biological tissue samples.  The extraction process was performed twice 
for each sample, as a second extraction improved fatty acid recovery in our lab and 
facilitates a cleaner transfer of the extract.  The ratio of tissue to organic solvent used 
(1:20 assuming a 300 mg tissue sample) is sufficient for extraction of tissues with lipid 
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content in excess of those found in this study (Iverson et al. 2001), and eliminates 
concerns with tissue-specific differences in total lipid content, or variations in the 
extraction efficiency of specific fatty acid types due to affinity/solubility in the organic 
solvent. 
 Tissue samples were transferred to a 20 mL glass vial containing 6 mL of a 1:1 
chloroform/methanol mix (10mg/L BHT).  Samples were homogenized for 1 minute 
using a homogenizer (Brinkman polytron) and visually inspected to ensure that 
homogenization was thorough.  Samples were transferred to 15 mL glass tubes, sealed 
under nitrogen, and spun down (Clinical Centrifuge) to pellet the tissue residue.  The 
supernatant was transferred to a glass conical tube containing 3 ml of distilled water to 
form a biphasic separation (Folch et al. 1957).  This sample was vortexed for 1 minute, 
then centrifuged as before, after which the organic (bottom) layer was transferred to a 
second 15 mL glass tube (collection tube).  A second extraction was performed on the 
remaining aqueous phase using an additional 3 mL of chloroform, a volume which 
maintains the organic/aqueous solvent ratio reported by Iverson (Iverson et al. 2001).  
The extraction process was repeated (vortex/spin), and the second organic aliquot was 
added to the original collection tube. This extraction was then placed in a warming block 
(~40°C) and dried under a stream of nitrogen.  After the solvent completely evaporated, 
the sample was reconstituted in 500 uL of hexane.   
 
Polar/Neutral Fraction Separation 
Separation of polar (membrane) and neutral (storage) fractions was performed 
using solid phase extraction columns by a method previously described (Juaneda and 
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Rocquelin 1985).   The choice of eluent alters the affinity of the analytes (polar vs. 
neutral) to the silica stationary phase.  The solubility of the neutral fraction in chloroform 
is greater than that of the polar fraction, allowing for a fast elution of the neutral fraction 
and retention of the polar fraction.  The retained and theoretically isolated polar fraction 
was eluted using methanol (decreases affinity of polar fraction to silica).  Efficient 
separation of the two fractions was validated prior to running test samples by measuring 
the recovery of known amounts of applied lipid fraction.  Fish oil (triaclyglycerides) and 
phosphotidylcholine (Sigma) were used for this purpose. 
Prior to sample loading, solid phase extraction cartridges (Sep-pack “classic” SPE 
cartridges, 690 mg Waters) were charged with 5-10 mL of chloroform.  Lipid extracts in 
hexane (~500 uL) were transferred to the column, and elution of the neutral fraction was 
achieved by passing 20 mL of chloroform in 60 seconds using a glass syringe.  The polar 
fraction was subsequently eluted by passing 30 mL of methanol through the cartridge, 
again for 60 seconds.  Fractions were collected in glass 250 mL round flasks, and solvent 
was removed using a rotovap (~45-50°C, vacuum~18 inches HG).  After solvent 
removal, two chloroform rinses of 2 mL each were used to recover lipid fractions from 
the flasks.  Recovered fractions were transferred to 15 mL round bottom glass tubes and 
dried down under nitrogen.  Fractions were reconstituted in 1 mL toluene for storage and 
subsequent methanolysis. 
SPE cartridges were rinsed with 20 mL methanol and 20 mL chloroform prior to 
the next use.  A single SPE cartridge was used for the separation of 6 fractions (Juaneda 
and Rocquelin 1985), after which it was discarded. 
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Fatty Acid Methyl Ester (FAME) synthesis: 
 Fatty acids were derivitized to facilitate detection/separation during gas 
chromatography.   Underivitized fatty acids are non-volatile and present adsorption issues 
during analysis.  Fatty acids methyl esters (FAME) are more easily vaporized and 
therefore move through the GC column more efficiently.  Additionally, FAME are more 
stable than their fatty acid counterparts, which is beneficial both for analysis and 
extended periods of storage.  Base catalyzed methanolysis (reaction below) provides an 
inexpensive, fast, and efficient (95%+ yield) means of derivitization and was employed in 
this research effort.   
 
 
The process is a transesterification which dissociates the fatty acid from the 
glycerol molecule and replaces the newly available bonding site on the fatty acid with a 
methyl group (CH3).  This derivitization is sufficient for both phospholipid and 
triacylglyceride-bound fatty acids and was therefore usable for both the polar and neutral 
fractions.  Widespread use of these fatty acid derivatives (fatty acid methyl esters, or 
FAME) provides an extensive understanding of their analysis and multiple options for 
established and validated GC separations.  Additionally, GC stationary phases have been 
specifically designed (for example, “FAME-WAX” columns by Restek, Inc.) to optimize 
retention/separation of these analytes, resulting in greater peak symmetry, baseline 
resolution, and retention consistency.  For these reasons, validation of the GC method 
employed was not required.  However, minor modifications to established methods were 
used to optimize the separation for the purposes in this research.  Reference Appendix C 
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and the Gas Chromatography section below for details regarding the chromatographic 
method used.    
 For methanolysis, fatty acid fractions in 1 mL toluene were transferred to 15 mL 
conical glass tubes containing 2 mL of methanolic base (metallic sodium in anhydrous 
methanol, 0.6N).  The presence of water decreases the yield of the derivitization, so a 
drop of methyl acetate was added to adsorb any residual water prior to initiating the 
reaction and provide consistency of derivitization.  Tubes were sealed under nitrogen to 
minimize oxygen exposure and were vortexed for 10 seconds to ensure adequate mixing.  
The mixture was heated at 50 °C in a warm water bath for 10 minutes, after which the 
tubes were removed from the water bath and were allowed to cool for 1 minute.  Two 
drops of glacial acetic acid were added to stop the reaction, after which 1 mL of hexane 
and 1 mL of double distilled water were added to the tubes.  Samples were vortexed 
briefly (10 seconds) to ensure adequate mixing, during which impurities with higher 
water solubility were separated from the FAME.  The sample was then spun for 1 minute 
to separate layers, after which the lower water/methanol layer was transferred to a second 
15 mL glass conical tube.  To this, 1 mL of hexane was added, vortexed, and spun as 
before to provide a second recovery.  The uppermost layer (hexane + FAME) of this 
separation was then added to the initial recovery sample.     
 This sample was vortexed briefly and spun to concentrate any remaining water 
into the bottom of the tube.  Any residual water visible in the bottom of the tube was 
carefully removed with a Pasteur pipette, after which approximately 30 mg of sodium 
sulfate (hygroscopic) was added to the tube to adsorb any water not collected with the 
pipette.  The sample was then placed in a warming block and dried down under a stream 
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of nitrogen until the volume of the sample was 100 uL or less, at which point the sample 
was transferred to a pre-weighed glass vial and dried down (completely) under a stream 
of nitrogen.  After drying, the vial was reweighed to determine the absolute amount of 
FAME present in that sample.  These data were useful in determining an appropriate 
amount of hexane with which to reconstitute the sample to provide consistent sample 
concentrations for chromatographic analysis.  Reference Appendix C for additional 
information regarding the utility of this sample weight. 
 For purposes of GC detection and extended storage, hexane (including an internal 
standard – see below) was added to FAME samples in an amount to provide a final 
FAME concentration adequate for detection on the GC.  Based on previous validation 
work in lab, the ratio of hexane to recovered FAME used was approximately 35 uL of 
hexane for 1 mg of FAME, but this was adjusted as necessary depending on the response 
of the chromatograms.  Due to the high evaporative rate of hexane, the ratio of hexane to 
sample could not be relied upon following reconstitution.  Consequently, chromatograms 
that provided peak responses too low to detect were in many cases concentrated (by 
allowing hexane evaporation) and re-injected.  Similarly, chromatograms that exhibited 
peak responses (areas) in excess of levels determined to be within the determined linear 
response were diluted and re-injected.   
The chosen hexane/FAME ratio provided a volume adequate for GC analysis (17-
35 uL) even for samples with low FAME yields (0.5-1.0 mg).  Furthermore, FAME 
yields using the methods described above were adequate and provided an excess of 
material for GC analysis even for samples that exhibited the lowest FAME quantities (the 
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quantity of reconstituted fame required for injection is only 1 uL).  Therefore, deviation 
from the above procedures was not required for any samples.  
 
Gas Chromatography   
  FAME were analyzed by gas chromatography.  A Hewlett-Packard 5890 
series II Gas Chromatograph equipped with a microcapillary column using a stationary 
phase designed for the analysis of FAME (Restek FAMEWAX Crossbond PEG, 30 
meter, 0.25 mm ID) was used for chromatographic analysis.  Detection was achieved 
using a flame ionization detector (FID), a standard means of detection for these fatty acid 
derivatives.  Data output was performed by a Hewlett-Packard 3396 Series III integrator.  
The chromatographic method employed was as follows: 
Injector temperature: 130°C 
Detector temperature: 230°C 
Initial column temperature : 130°C 
Temperature ramp : 6°C/minute for 15 minutes, followed by a 15 minute hold 
Split ratio : 10:1 
Injection volume: 1 uL 
Carrier Gas: Helium 
 
 Methods similar to this (e.g. Restek #108-01[001]) have been shown to be 
effective in the separation and quantification of a large number of physiologically 
common fatty acids, 33 of which were considered for this study (Appendix E).   
Fatty acid methyl ester (FAME) standards were procured from Nu-Chek Prep, 
Inc., and were analyzed using the above method to determine and assign retention times 
for the various analytes of interest.  Known concentrations of the standards allowed for 
the determination of signal response factors for individual FAME (signal 
strength/amount), which are expected to differ based on differences in molecular weight 
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(larger molecules typically respond with higher response due to increased conductance 
per molecule).  Calculated response factors specific to each FAME were uploaded to the 
integrator, thus allowing the integrator to report data for identified peaks as both a 
measure of signal strength and a corrected amount.   
Additionally, the integrator identified and measured the signal from a single 
internal standard in each sample run.  This allowed the integrator to adjust the FID signal 
for the entire chromatogram to a preset internal standard ‘expected response’.  This 
adjustment accounts for any inconsistency in injection volume or variation that can occur 
from sample delivery to the column through the split injector.   As an added precaution, 
chromatograms were manually reviewed to ensure that peak responses did not exceed 
established upper limits of detection. 
 Resulting chromatograms provided data which were adjusted in two ways; 
normalization of data in response to the internal standard signal, and a recalculation of 
the signal strength for each analyte using the appropriate response factor.   Data 
generated was therefore indicative not of percent weight contribution to total fatty acid 
content of the sample, but is a measure of the relative number of fatty acid types, e.g. a 24 
carbon fatty acid would be expected to elicit a larger signal than a 10 carbon fatty acid.  
This difference is accounted for by the use of measured response factors for all reported 
fatty acids.     
 The internal standard was prepared by dissolving a synthetic FAME (C23:0) in 
BHT-treated hexane.  Naturally occurring fatty acids are typically synthesized/modified 2 
carbons at a time and consequently contain an even number of carbons.  The use of an 
internal standard with an odd number (23) of carbons greatly reduces the likelihood of 
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co-elution with FAME contained in the test samples.  Furthermore, the internal standard 
is structurally similar to the analytes of interest, and therefore is expected to be 
responsive to any variable/unwanted interference that might affect the elution of analytes 
in the test sample (e.g. purity of carrier gas, decomposition of stationary phase, failure to 
maintain temperature, etc).   
C23:0 was dissolved in hexane at a concentration of 0.25 ug/uL for use as a stock 
solution, from which “working aliquots” were transferred to 2 mL vials to reduce 
contamination or concentration changes due to gradual solvent evaporation.  Dried 
FAME samples from the various tissues examined in this study were resuspended in 
hexane to which a known amount of internal standard (23:0) had been added. 
 Reproducibility of the GC analysis was confirmed by comparison of multiple 
injections of both standards and samples.  To determine the upper limit of detection, 
standards were run at increasing concentrations (serial dilutions) and plotted to examine 
linearity of signal response.  The concentration at which the sample concentration/signal 
ratio loses linearity due to detector saturation was determined.   The upper limit of 
detection was set at 75% of this response (as determined by peak area).  Any test samples 
that contained peaks that exhibited areas above the upper limit of detection were further 
diluted in hexane and re-analyzed to ensure all peak areas were within the validated 
response limits.   
 Lower limits of detection were determined using the calibration curve.  Peak 
signals determined to be too small for reproducible detection were excluded from the data 
at the time of integration (minimum detectable peak signal).  When considering the high 
sensitivity of flame ionization detection (<1.0 ng) and the low contribution of these peaks 
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to the overall abundance of FAME in the sample, the fatty acid signature of any particular 
sample is essentially unaffected by the exclusion of trace FAME.  To prevent inadvertent 
exclusion of significant peaks when samples contain an unusually low absolute FAME 
concentration, chromatograms were checked to verify that a minimum of 20 FAME were 
detected by the integrator during each run.  Any samples that contained fewer than 20 
FAME were concentrated (i.e., partially dried under nitrogen) and re-injected until the 
resulting sample concentration was sufficient for a reliable report of the fatty acid 
signature. 
 
Data Reporting and Statistical Analysis 
Individual fatty acid values reported in tables, figures, and appendices are 
representative of the number of fatty acids (percent contribution of fatty acid units) in a 
given sample (percent contribution of fatty acid units).  As described on page 31 above, 
known response factors for the individual fatty acids were used to account for differences 
in detection strength.   
Fatty acid index values reported are the sum total of all applicable individual fatty 
acid values as described below and in Appendix E, pg 86.  Saturated Fatty Acids 
(saturates) represent the sum total of individual fatty acids  14:0, 16:0, 18:0, 20:0, 22:0, 
24:0.  Monounsaturated Fatty Acids (monoenes) represent the sum total of individual 
fatty acids: 14:1, 16:1, 18:1, 20:1, 22:1, 24:1.  Polyunsaturated Fatty Acids (PUFA) 
represent the sum total of individual fatty acids 16:2n4, 16:3n4, 16:4n1, 18:3, 18:4, 
18:4n1, 20:2, 20:3n6, 20:4, 20:3, 20:4n3, 20:5, 21:5n3, 22:4, 22:5n6, 22:5, 22:6. 
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Fatty acid indices are also reported for fatty acids of the n6, n3, n3 HUFA classes.  
Omega-6 (n6) fatty acids include 18:2, 18:3 (γ-Linolenic), 20:2, 20:3n6, 20:4, 22:4, 
22:5n6.  Omega-3 (n3) fatty acids include 18:3 (α-Linolenic), 18:4, 20:4n3, 20:5, 21:5n3, 
22:5, 22:6.  Omega-3 Highly unsaturated fatty acids (n3 HUFA) include 20:4n3, 20:5, 
21:5n3, 22:5, 22:6.  Finally, the  n3/n6 ratio is provided for all test groups. 
One-way ANOVA’s and post-hoc Tukey tests were used for comparison of initial 
fish and survivor test groups following the temperature challenge.  Comparison of fatty 
acid profiles of survivors and mortalities (both cold and warm) were made using t-tests.    
Data were arcsine transformed where appropriate, and significance for one-way 
ANOVA’s and t-tests was assumed at the p < 0.05 level.  SPSS v.14.0 statistical software 
(SPSS Inc, Chicago, IL, USA) was used for all statistical comparisons.     
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RESULTS 
 
For the purposes of reporting results, individual fatty acids to be reported and 
discussed below were selected based on overall contribution to the fatty acid signature 
and responsiveness to temperature challenges.  For clarity of presentation, fatty acids 
C16:0, C18:0, C18:1n9, C18:1n7, C20:4, C20:5, and C22:6 are the only individual fatty 
acids included in Figures 1-6.  All tested fatty acids were grouped and analyzed in 
appropriate fatty acid indices (reference Appendix E for detail) to capture overall trends 
of saturation/unsaturation in response to the temperature challenges.  These indices are 
commonly used in the field and can allow a basis for comparison across studies. 
Furthermore, reporting fatty acid composition change in fatty acid groups or classes can 
be more effective in identifying predicted changes in membrane order than by looking at 
responses of a large number of individual fatty acids (see below).   
Changes in PUFA are correlated with temperature acclimation (Olsen 1999) and 
are expected to increase in response to colder temperatures where modification of 
membrane composition is occurring in response to temperature.  Changes in SAFA can 
be expected to occur in opposition to PUFA as the predicted effect on membrane order is 
in opposition to that of PUFA.  Changes in SAFA can therefore be used to indicate 
change in membrane order/fluidity independently of PUFA results.  HUFA in the n3 class 
are in large part essential fatty acids in fishes and are therefore a class of interest when 
attempting to identify fatty acid dietary deficiencies.  n3/n6 ratios can be indicators of 
dietary sources and are of growing interest due to the importance of these ratios to 
eicosanoid/docosenoid production.  All fatty acid data generated in this study are 
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available in Appendix E and includes data for individual fatty acids and the calculated 
indices.   
Graphical representation of all the analyzed fatty acids would be of limited value 
as the majority of the individual fatty acids either did not exhibit statistically significant 
changes or were present in such low composition that the overall impact of the individual 
fatty acid on homeoviscous adaptation would be expected to be minimal.  For example, 
fatty acid C20:2 (eicosadienoic acid) in liver neutral samples responded to both cold and 
warm temperature treatments.  Differences between initial fish (1.3 ± 0.02%), cold 
survivors (1.5 ± 0.02%), and warm survivors (0.7 ± 0.02%) are statistically significant 
and are therefore potentially of interest.  However, as this fatty acid constitutes not more 
than 1.5% of the total fatty acid signature in any of the three samples, the implications of 
these results as they pertain to changes in membrane fluidity are not expected to be large 
due to the low abundance of the individual fatty acid.  These data are of greater interest 
when looked at as a contributor to overall polyunsaturated fatty acid change.  The change 
in levels of C20:2 in response to temperature is therefore captured in the appropriate fatty 
acid index (PUFA).  For these reasons, only select individual fatty acids which in most 
cases were those occurring in the greatest amounts are graphically presented in Figures 1-
6.  However, all statistically significant differences observed are reported in Tables 2-4. 
 
Initial “Control” samples vs Survivors of Temperature Challenges 
 
 
Gill Tissue 
 
 
Gill storage lipids were generally not responsive to either the cold or warm 
temperature challenges (Figure 1).  When considering all individual fatty acids and the 
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calculated fatty acid indices, the only significant change was observed in the individual 
fatty acid DPA (C22:5n3): warm survivor DPA levels (2.5 ± 0.05%) were significantly 
higher than DPA levels in initial fish (2.2 ± 0.09%). 
Gill membrane lipids were very responsive to the temperature challenges when 
compared to the neutral lipids (Figure 1).  In response to the cold challenge, gill 
membrane lipids of survivors had significantly lower levels of C16:0 and SAFA.  In both 
cases, the change was an approximate 20% decrease from initial levels.  The cold 
challenge also resulted in increases in three individual fatty acids, C18:1n7 (vaccenic), 
ARA (C20:4n6) , and DHA (C22:6n3) as shown in Figure 1.  Furthermore, PUFA, total 
n6, total n3, and n3 HUFA levels were all significantly higher than levels found in initial 
fish (Figure 1).   The change observed in PUFA in the cold challenge gill polar samples 
represents a 25% increase over initial levels. 
 In response to the warm challenge, gill membrane lipids showed little change.  
The only significant change in individual fatty acids was a decrease in the level of 
C18:1n-7.  No significant changes were observed in the fatty acid indices, and as 
illustrated in Figure 1, gill membrane lipids were generally more responsive to the cold 
challenge than the warm challenge.   
  
Liver Tissue 
 
Liver storage lipids exhibited a number of changes in response to both warm and 
cold temperature challenges.  With regard to the cold temperature challenge, significantly 
lower levels of C16:0 and SAFA were observed in cold challenge survivors when 
compared to initial fish.    Of interest, the decrease in SAFA in the cold challenged liver 
storage fatty acids is almost entirely attributable to the decrease in the individual fatty 
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acid C16:0.  Conversely, significantly higher levels of both C16:0 and SAFA were 
observed in the neutral lipids of warm challenged fish (Figure 2).    
Liver storage lipids in warm temperature challenged fish also exhibited a 
statistically significant increase in DHA (C22:6n3) along with increases in several of the 
fatty acid indices.  Increases in total PUFA, total n3, n3 HUFA, and n3/n6 ratios were 
also observed, and C18:1n9, C18:1n7, and MUFA all decreased significantly in these 
tissues (Figure 2).   
Liver membrane lipids were also responsive to both temperature challenges.  
Levels of the individual fatty acid C18:1n7 changed significantly in response to both 
challenges, exhibiting higher levels in response to the cold challenge and lower levels in 
response to the warm temperature challenge.  In addition to the reduced levels of 
C18:1n7 observed in the warm temperature challenge, survivors showed reduced levels 
of two other unsaturated fatty acids, C18:1n9 and EPA (C20:5n3), and reductions in the 
amounts of MUFA, PUFA and total n6 (Figure 2).   Warm survivors also exhibited 
significantly higher C16:0, C18:0, SAFA and n3/n6 ratios.  Generally, more changes in 
liver lipids resulted from the warm temperature challenge than the cold temperature 
challenge. 
 
Muscle Tissue 
 
Muscle storage lipids were generally unresponsive to both the cold and warm 
temperature challenges.  The only statistically significant difference observed was a 
decrease in eicosenoic acid (C20:1) in warm challenged fish when compared to initial 
fish (Table 4).   
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Membrane lipids in muscle tissue did not exhibit significant changes in response 
to the cold challenge.  However, membrane lipids in muscle tissue were responsive to the 
warm temperature challenge as evidenced by changes in individual fatty acids and fatty 
acid indices.  With regard to individual fatty acids, an increase C16:0 and a decrease in 
C18:1n7 were observed.  Fatty acid indices for muscle polar lipids exhibited increases in 
SAFA and decreases in PUFA and total n6 in response to the warm temperature 
challenge (Figure 3).  In this study, results indicate that the warm temperature challenge 
promoted greater fatty acid change than did the cold temperature challenge. 
 
 
Survivor and Mortality Comparisons 
 
Gill Tissue 
 
Gill neutral fatty acids signatures were essentially identical for both the warm and 
cold temperature challenge survivor and mortality samples.  Similarly, gill membrane 
lipids were essentially unchanged in response to the cold challenge when comparing 
survivors to mortalities (Figure 4).  However, a number of significant differences existed 
between survivors and mortalities for fish subjected to the warm temperature treatment.  
Warm mortalities had higher levels of SAFA when compared to warm survivors.  
Furthermore, warm mortalities showed significantly lower levels of DHA (C22:6n3) 
(approximately 33% less DHA than levels present in warm survivors).  Several fatty acid 
indices were significantly lower in warm mortalities (vs survivors), including PUFA, 
total n3, n3 HUFA, and n3/n6 ratios (Figure 4). 
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Liver Tissue 
 
Fatty acids in liver storage lipids in survivor and mortality groups were essentially 
identical in cold challenged samples, but demonstrated a number of differences in the 
warm temperature challenges (Figure 5).  Similar to what was observed for gill polar 
lipids in warm mortality samples, levels of DHA (C22:6n3)  in liver storage samples of 
mortalities were significantly lower than those of survivors (levels of DHA were 
approximately 30% lower than found in the comparable survivor tissue).  There were also 
several significant differences in the fatty acid indices for these test groups, as warm 
mortalities showed lower levels of PUFA, total n6, total n3, n3 HUFA, and lower n3/n6 
ratios when compared to survivors (Figure 5).   
Liver polar lipids exhibited differences between survivors and mortalities as well, 
but again only in response to the warm temperature challenge.  Levels of individual fatty 
acids C18:1n7 and ARA (C20:4n6) were significantly higher in warm mortalities, and 
levels of DHA (C22:6n3) were significantly lower in these samples when compared to 
warm survivors (Figure 5).  The fatty acid indices demonstrated a number of significant 
differences, including higher levels of MUFA and total n6 (opposite of what was 
observed in the liver neutral lipids mortalities), and decreases in PUFA, n3, n3 HUFA, 
and the n3/n6 ratio in mortalities when compared to surviving fish (Figure 5).   
 
Muscle Tissue 
 
Muscle neutral lipids did not demonstrate any significant differences in either the 
warm or cold temperature challenge when comparing survivors to mortalities (Figure 6).  
There were, however, two statistically significant differences in muscle polar lipids.  
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Cold mortalities exhibited higher levels of C16:0 and lower levels of C18:1n7 when 
compared to cold survivors (Figure 6).  There were no significant differences in polar 
lipids of the warm temperature challenged fish when comparing survivors to mortalities.  
 
Survivorship in Response to Temperature Challenges 
 
As discussed on page 19 above, mortality samples were to be removed and 
recorded throughout the duration of the temperature challenges.  Mortality specimens 
would be selected for lipid analysis with a preference for mortalities that occurred toward 
the end of the study.  The intent was to provide samples that would most closely match 
the surviving counterpart with regard to time and temperature exposure.  This approach 
was expected to provide more valuable comparisons than, for example, a comparison of 
15 day warm temperature mortality fish to 32 day warm temperature survivors.   
As seen in Table 1, the majority of mortality events occurred in the last few days 
of the study and therefore occurred almost concurrently with survivor fish sampling.  
Consequently, selection of mortality samples did not require inclusion of mortality 
specimens that died several days or weeks prior to the sampled survivor fish.  The warm 
challenge was extended beyond the originally intended 30 days to ensure mortalities 
occurred. 
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DISCUSSION 
This study explored changes in stored fatty acid reserves and biomembrane fatty 
acid composition in response to changing temperatures (homeoviscous adaptation), and 
ultimately provides data to help predict the implications of these adaptations on 
freshwater alewife survivability in response to temperature change.  Previous work with 
this species demonstrated that changes in fatty acid composition in response to cold 
temperature stress were in accordance with predictions made by homeoviscous 
adaptation, in that increased HUFA and PUFA (and decreases in SAFA) were observed 
in whole body analysis of alewives (Snyder and Hennessey 2003).  The tissue-specific 
data generated in my study indicates that fatty acid composition in membrane and storage 
lipids changes in response to both cold and warm temperature challenges, and these 
results provide further evidence of homeoviscous adaptation in alewives.  In addition, 
comparisons among tissues demonstrate tissue specific lipid modification in response to 
temperature, as the changes that occurred in individual fatty acids and fatty acid classes 
were not shared among the tissues I examined.   
 Polar lipids from alewives subjected to the cold temperature challenge would be 
expected to demonstrate decreased saturation to counter the decrease in membrane 
fluidity that results from thermodynamic interaction between fatty acids.  Gill polar lipids 
responded accordingly, demonstrating significant decreases in the saturated fatty acid 
C16:0 (palmitic acid) and in SAFA as a whole.  Increases in the unsaturated fatty acids 
DHA (C22:6n3) and ARA (C20:4n6) were also observed in this tissue, which would be 
expected to maintain membrane fluidity in response to the low temperatures.  
Furthermore, HUFA and n-3 fatty acids, as well as n-6 fatty acids, showed significant 
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increases.  Each of the above changes are indicative of homeoviscous adaptation (Hazel 
1993), and support the likelihood that gill tissue membranes are responsive to cold 
temperatures by remodeling membrane fatty acid signatures. 
 Polar lipids (membrane fatty acids) of both liver and muscle tissue were 
essentially unaffected by the cold temperature challenge.   There was an increase in the 
level of C18:1n7 observed in the liver tissue of cold challenged fish, but overall the data 
indicate that membrane fatty acid composition of liver and muscle tissue of alewives are 
unresponsive to cold temperature challenge as performed in this study.  Though these 
results were not anticipated, they demonstrate the tissue-specific nature of the 
homeoviscous adaptation response and support the importance of examining these 
changes at the tissue versus whole body level (discussed further below).   
 Polar lipids in warm challenged survivor samples were expected to undergo 
changes in opposition to those of the cold temperature challenge.  Increases in the relative 
amount of saturated phospholipids, and decreases in membrane HUFA and PUFA would 
be predicted to occur during warm acclimation due to the resulting increase in membrane 
order that would be needed to offset the temperature-induced increase in membrane 
fluidity (Hazel and Williams 1990).  Under the premise that membrane function is 
optimal at a specific fluidity/order, the increased inclusion of saturated fatty acids could 
provide the additional viscosity/inter-membrane order needed to effectively return 
membrane order to the desired state.   
There are multiple means by which increased membrane saturation could take 
place.  One possibility would be for cells to undergo small to moderate changes in the 
quantities of a number individual saturated fatty acids (e.g. C14:0, C16:0, C18:0, C20:0).  
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Another possibility would be to reduce HUFA levels and increase MUFA (or possibly 
PUFA), as the overall decrease in the number of double bonds would generally be 
expected to decrease membrane interaction and therefore “thicken” the membrane.  Per 
unit double bond, monoenes (MUFA) have a greater impact on modifying physiological 
properties of membranes than more highly unsaturated fatty acids (Hazel 1995) and for 
this reason could serve as a medium for increased membrane fluidity.  However, a 
modification of membrane composition from low to high MUFA could increase the order 
of a cell membrane if the increase in MUFA occurred concurrently with a decrease in 
HUFA, PUFA, or both.  Another approach to increase membrane order or viscosity 
would be for cell membranes to undergo a large increase in the amount of a single 
saturated fatty acid.   
In liver and muscle tissues, increases in SAFA indices were significant, but in 
both cases this increase was nearly entirely attributable to an increase in a single fatty 
acid, palmitic acid (C16:0; see Figures 2 and 3).   As described in the results section 
above, levels of palmitic acid doubled in both liver and muscle membranes of warm 
challenge survivors.  In liver membranes, C18:0 also increased dramatically (2x), but this 
fatty acid accounted for less than 5% of membrane composition in initial samples and 
less than 10% in the warm survivors.  In contrast, palmitic acid accounted for over 30% 
of membrane fatty acid composition in warm survivors versus approximately 15% in 
initial fish.   Of the several mechanisms by which a cell might increase saturation in 
response to increasing temperatures, in this study the increased saturation was largely 
accounted for by the increased inclusion of palmitic acid in both liver and muscle tissues. 
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 One expectation of this study was that of the three tissues, phospholipids from the 
gill would be the most responsive to the temperature challenges.  This was predicted 
based on the importance of the gill in osmoregulatory function, and the association of 
compromised osmoregulatory function as a suspected cause of winter mortality in this 
species in the Laurentian Great Lakes (Stanley and Colby 1971).  As discussed above, 
gill phospholipids were highly responsive to the cold challenge.  However, they were 
essentially unresponsive to the warm challenge with regard to modification of fatty acid 
signatures.   In light of the significant fatty acid signature modification of both liver and 
muscle phospholipids in response to warm temperatures, the possibility remains that gill 
membranes were responsive to warm temperatures as tested in this study, but that the 
acclimation/response resulted from a mechanism other than changes in fatty acid 
composition (e.g. molecular species remodeling, changes in cholesterol incorporation, 
polar head group modification etc.).  A growing body of evidence supports tissue-specific 
responses to temperature stress and further study is required to better understand the 
complexities of these responses (Crockett and Londraville 2006).  However, based on the 
results of this study, it appears gill phospholipids do not undergo significant changes in 
fatty acid composition in response to warm temperatures as tested in this study. 
It was anticipated that changes in stored lipids (neutral fraction) would reflect the 
lipid modification that occurs in the membrane (polar).  The rationale for this hypothesis 
was twofold.  First, increases or decreases in those lipids required to maintain membrane 
fluidity might undergo a similar change in lipid stores to ensure appropriate amounts of 
the required fatty acids are available for use in membranes.  Secondly, though 
homeoviscous adaptation is primarily thought of as a membrane response, there is 
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increasing evidence that changes in fatty acid composition are applicable to stored lipids 
for similar thermodynamic reasons.   For example, as temperatures decrease, storage 
lipids become less fluid and their availability as substrates for lipases can be 
compromised (Kostal and Simek 1998).   Maintaining lipid fluidity in triaclyglycerols is 
consequently of great importance to ensure bioavailability of these lipids for both energy 
and for transport and use as membrane components.   
Data from this study demonstrate that, in some cases, the responses of stored lipid 
to changes in temperature show patterns that are similar to those observed in membrane 
lipids.  For example, in warm-challenged alewives, membrane and storage lipids of liver 
tissue exhibited significant increases in C16:0 and SAFA, and significant decreases in 
C18:1n9, C18:1n7, and MUFA.  However, as discussed further below, there are 
numerous examples of lipid change in the neutral fractions which do not mirror the 
changes in the polar fraction.  Furthermore, there are examples in which the observed 
changes in the polar and neutral lipids of a given tissue actually respond in opposition to 
each other.   
In liver tissue of warm-challenged fish, PUFA decreased significantly in 
membrane lipids when compared to initial fish.  This decrease in unsaturated fatty acids 
is what would be predicted by homeoviscous adaptation theory, as the removal of double 
bonds (in the form of PUFA in this case) would lead to increased membrane order to 
counter the disordering effect of increased temperatures.  However, the opposite response 
occurred in PUFA in stored lipids of warm challenged alewives, and the levels of this 
fatty acid class underwent a significant increase.  Another example can be found in the 
response of DHA (C22:6n3) in liver tissue.  Membrane lipids in liver tissue of warm-
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challenged fish remained unchanged with regard to levels of DHA.  DHA levels would 
therefore be expected to remain unchanged if neutral fractions generally mirrored the 
responses of the polar fraction.  However, DHA levels increased significantly (nearly 
doubled) in the neutral fraction of warm-challenged liver tissue.  Not only was this 
response dissimilar to that seen in the polar lipids found in the membranes of this tissue, 
the response is in opposition to what is predicted by homeoviscous adaptation.  In 
response to warmer temperatures, increased saturation of the fatty acids would be 
expected as this would counter the decreased membrane order that results from increasing 
temperatures.  A doubling of DHA represents a large decrease in saturation (DHA 
contains 6 double bonds).  This response, however, may be to preserve stores/availability 
of this essential fatty acid as it is not readily available in freshwater alewife diets (Snyder 
and Hennessey 2003) and is needed as a precursor to hormone-like compounds (e.g. 
eicosanoids) essential for proper cellular and organismal function in fishes (Henderson 
and Tocher 1987). 
One hypothesis of this study was that changes in membrane fatty acid signature 
would be reflected by the stored lipid counterpart (pg. 45).  Analysis of the liver tissue in 
warm survivors discussed above indicates that this premise is not correct and that the 
modifications to fatty acid composition are complex and cannot be assumed to correlate 
to changes observed in cell membranes.  Not only are changes that occur in membrane 
lipids not necessarily mirrored by their neutral counterparts, but responses of individual 
fatty acids or fatty acid indices may undergo a change counter to what was observed in 
the polar fractions.  For example, as observed in Figure 2, PUFA levels in storage lipids 
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increased in response to the warm temperature challenge yet showed a statistically 
significant decrease in the membrane fraction of warm survivors.   
I compared fatty acid composition of survivors and mortalities in each treatment 
to identify where significant differences in fatty acid signatures existed.  Where evidence 
of fatty acid signature modification is evident in survivors, a comparison against 
mortalities might provide an opportunity to identify a failure to maintain appropriate 
membrane fluidity.  By examining the predicted impact of these differences on 
membrane fluidity, we might gain a better understanding of which lipid modifications are 
most critical for alewife survival in response to changes in ambient temperature. 
Comparison of survivors and mortalities in cold challenged fish indicate very few 
differences in the tested tissues.  In both liver and gill tissues, no differences were 
observed in either the membrane or storage lipids of survivors and mortalities in response 
to the cold challenge.  However, in muscle membrane lipids, there were significant 
differences between survivors and mortalities in two fatty acids.  Cold survivors 
exhibited higher levels of C18:n7 in membrane lipids of muscle tissue, but this change 
would be expected to have little impact as the fatty acid accounts for less than 5% of the 
total membrane composition.  However, palmitic acid (C16:0) was present in 
significantly lower amounts in cold challenge survivors.  This observation is in 
accordance with previous research, where higher levels of SAFA were associated with 
cold challenge mortality in alewives (Snyder and Hennessey 2003).   Furthermore, the 
abundance of palmitic acid has been identified as a key difference in membrane 
composition of cold and warm acclimated fish species, where considerably higher levels 
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of palmitic acid have been found in cell membranes of warm acclimated fish (Palmerini 
2009).   
When comparing palmitic acid levels in muscle membranes of initial fish to cold 
survivors, it is apparent that the amount of palmitic acid did not decrease in response to 
the cold challenge.  However, the increased inclusion of palmitic acid in the cold 
temperature mortalities may have been the critical factor in the mortality of cold-
challenged fish.  Addition of palmitic acid would contribute to membrane order in system 
where membrane order is already being increased (by a decrease in temperature) and 
away from optimal fluidity.    
As mentioned above, survivor and mortality comparisons of warm-challenged fish 
indicate a number of significant changes in gill and liver tissue, but none in muscle tissue.  
In gill tissue, differences in fatty acid signatures were limited to membrane lipids, where 
decreases in DHA (C22:6n3), PUFA, n3, and n3 HUFA were observed. All of these 
differences in membrane composition, as well as the observed increase in SAFA, would 
be expected to provide increased membrane order when compared to the survivors.  
Implications of these observations to membrane fluidity, speaking strictly to predicted 
changes in response to membrane lipid composition (not accounting for changes in polar 
head groups, molecular remodeling, cholesterol incorporation, etc.) are that mortalities 
were better suited to address the decreased order that resulted from the increasing 
temperatures.   
Similarly, liver tissues of warm temperature survivors and mortalities exhibited a 
number of fatty acid differences in storage and membrane fractions.  Differences shared 
in both membrane and storage lipids were decreases in DHA (C22:6n3), PUFA, n3, and 
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n3 HUFA.  Again, assuming changes in membrane fluidity based solely on fatty acid 
composition, each of these differences would be predicted to increase membrane order, 
and effectively counter the decreased order that occurs at higher temperatures.  As 
concluded for the gill tissues, the differences in survivors and mortalities actually suggest 
that mortalities were better suited to address the warm temperature challenge than the 
survivors. 
Membrane physiology and fluid dynamics are extremely complex.  Modification 
of lipid composition of biomembranes has been demonstrated in response to temperature 
changes using a variety of approaches in fish species, including changes in cholesterol 
incorporation, molecular species remodeling (Hazel and Landrey 1988) and modification 
of polar head groups of phospholipids (Greene and Selivonchick 1987).  The analysis of 
fatty acid signatures as performed in this study does not account for changes in polar 
head groups or membrane remodeling.  The use of fatty acid signatures and changes in 
lipid classes (degree of saturation) was selected due to its use in a variety of organisms to 
address thermal stress, and this response has been shown to be prevalent in a variety of 
fishes (Hazel and Williams 1990).  Moreover, previous work has indicated that alewives 
alter fatty acid composition in response to temperature changes (Snyder and Hennessey 
2003).   
 The differences demonstrated in fatty acid composition of survivors and 
mortalities in this study are potentially a reflection of a number of factors, including 
increased use of n3 and n6 fatty acids as eicosanoid/docosenoid precursors in response to 
stress, changes in energy demands, the inability to feed effectively towards the end of the 
challenges, or other physiological disruptions.  However, as many of the observed 
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differences are in opposition of what would be expected from our current understanding 
of homeoviscous adaptation, for this species future studies of response to warm 
acclimation should consider additional factors (e.g. polar head composition and 
molecular remodeling) in addition to the extent of lipid saturation.   Furthermore, this 
species may not prove to be an effective model to identify warm acclimation response as 
it is generally considered a cold-adapted organism and is likely to avoid warm 
temperatures in nature (Colby 1973). 
 
Conclusions 
Evidence of changes in fatty acid composition in response to temperature were 
found in all tissues tested, and this study provides further evidence of homeoviscous 
adaptation response in alewives.   With regard to comparisons of initial fish to survivors 
of the temperature challenges, results were generally in accordance with expectations of 
homeoviscous adaptation theory.  In cold-challenged alewives, polar lipids in gill tissues 
exhibited decreases in SAFA and increases in n3 and n6 HUFA, and polar lipids in liver 
and muscle tissue from warm-challenged alewives displayed increases in SAFA and 
decreases in PUFA.  The changes in lipid saturation that were observed in survivors 
strongly correspond to anticipated requirements to maintain appropriate membrane 
fluidity.   
In polar tissues of cold-challenged alewives, the increases in HUFA (n3 and n6) 
observed in the gill may be of ecological importance to populations of this species in the 
Laurentian Great Lakes, as abundance of these fatty acids in fresh water systems is low 
relative to those found in marine environments (Arts and Kohler 2009).  These results 
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suggest that in fresh water habitats, the scarcity of these essential fatty acids in the 
alewife diet may leave populations susceptible to cold temperature stress and mortality 
due to an inability to effectively increase membrane composition of n3 and n6 fatty acids, 
the acclimation response observed in the cold water challenge in this study.  Lastly, 
results of this study indicate that changes in lipid composition are highly tissue-specific, 
and differ greatly for both cold-challenged and warm-challenged alewives. 
 
Future Research 
 The differences observed in survivors and mortalities in the warm temperature 
challenge were unexpected, as the majority of lipid differences were in opposition of 
what would be predicted by homeoviscous adaptation theory.  If homeoviscous 
adaptation is occurring, these data suggest that other factors, potentially molecular 
species remodeling or polar head group changes, may be involved and require further 
study in this species.     
Regarding execution of the temperature challenges, the rate of temperature 
change, as well as the start and finish temperatures used in this study, proved very 
suitable as mortality events occurred towards the end of both temperature challenges with 
little modification to the proposed temperature regime.  Moreover, the consistency of 
lipid analysis (i.e. little variation in triplicate data for survivors) indicates that sufficient 
time was provided for individuals to acclimate.  A more rapid change in temperature 
during the experiments may have had the consequence of challenging the populations so 
quickly that temperature acclimation may not have been given sufficient time to occur. 
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 It should be noted that the lengthy conditioning phase performed prior to the 
temperature challenges was critical to the experiment.  At the onset of the conditioning 
phase, the change in diet to frozen Mysis from a previous diet of dried prepared fish food 
precipitated a number of changes in fatty acid composition (Wei 2007).  These changes 
occurred in the first few weeks of the conditioning period and were confirmed by GC 
analysis over the course of the nine week conditioning phase.   By verifying stability of 
fatty acid signatures prior to the execution of the temperature challenge, the initial fish 
could confidently be used as a control for temperature-challenged fish.  This is common 
practice in the field, but of the factors known to modify fatty acid signature (other than 
temperature), changes in diet are one of the more pronounced.  Should a study of this 
type be repeated it is recommended that a lengthy conditioning phase be performed and 
that fatty acid signatures demonstrate stability following the change in diet prior to 
execution of the temperature challenges.  A separate group of unchallenged fish would be 
useful as an additional control.  However, establishing a baseline lipid signature is more 
critical to observing temperature effects than comparison to a population maintained at 
initial temperatures that has not fully adjusted to the change in dietary lipid. 
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Table 1. Temperature challenge design and survivorship. 
 
Cold Temperature Challenge Design 
 Initial 
Temperature 
Temperature 
at 25 Days 
Temperature 
at 31 days 
(Final) 
Tank C1 15°C 1.1°C 1.1°C 
Tank C2 15°C 1.1°C 1.1°C 
Cold Temperature Challenge Survivorship 
 Initial 
Number of 
Fish 
Final 
Number of 
Fish  
Percent 
Survival (%) 
Tank C1 20ª 13 65 
Tank C2 25 6 24 
All mortality occurred during the last five (5) days of the cold 
challenge (days 27-31) 
Warm Temperature Challenge Design 
 Initial 
Temperature 
Temperature at 
39 Days (Final) 
Tank W1 15°C 34.0°C 
Tank W2 15°C 34.0°C 
Warm Temperature Challenge Survivorship 
 Initial 
Number of 
Fish 
Final 
Number of 
Fish 
Percent 
Survival (%) 
Tank W1 25 17 68 
Tank W2 25 17 68 
All mortality occurred during the last three (3) days of the warm 
temperature challenge (days 37-39) 
ª All tanks originally stocked with 25 fish per tank.  Mortality in 
tank C1 occurred several weeks before the temperature challenge 
resulted in an initial N of 20. 
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Table 2. Statistically significant changes in fatty acid composition (% of 
total fatty acids) of gill tissue in initial, cold-challenged and warm-
challenged survivors. Data are X  ± SE.  Mean values marked with 
different letters indicate statistically significant differences at p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Initial Cold Challenge 
Survivors 
Warm Challenge 
Survivors 
Neutral FA    
DPA (22:5) 2.2 ± 0.09 a 2.2 ± 0.02 a 2.5 ± 0.05 b 
Polar FA    
Palmitic (16:0) 27.9 ± 0.84 a 22.1 ± 0.79 b 29.9 ± 0.53 a 
(16:3n4) 0.5 ± 0.04 ab 0.6 ± 0.03 a 0.4 ± 0.01 b 
Oleic (18:1) 12.1 ± 1.14 ab 10.5 ± 0.09 a 14.5 ± 0.40 b 
Vaccenic (18:1) 5.1 ± 0.29 a 6.2 ± 0.03 b 3.8 ± 0.08 c 
Eicosen (20:1) 0.9  ± 0.11 ab 1.0 ± 0.11 a 0.5  ± 0.05 b 
Eicosad(20:2) 0.7 ±  0.3 ab 0.7 ± 0.002 a 0.5 ±  0.03 b 
Arachidonic (20:4) 5.0 ± 0.32 a 6.2 ± 0.15 b 4.2 ±  0.13 a 
EPA (20:5) 3.5 ± 0.24 ab 4.4 ± 0.26 a 2.8 ± 0.20 b 
(22:5n6) 2.1 ± 0.08 a 3.0 ± 0.05 b 2.0 ± 0.14 a 
DPA (22:5) 1.2 ± 0.10 ab 1.5 ± 0.03 a 1.1 ± 0.04 b 
DHA (22:6) 17.5 ± 0.71 a 22.5 ± 0.30 b 18.0 ± 0.83 a 
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Table 3. Statistically significant changes in fatty acid composition (% of 
total fatty acids) of liver tissue in initial, cold-challenged and warm-
challenged survivors. Data are X  ± SE.  Mean values marked with 
different letters indicate statistically significant differences at p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Initial Cold Challenge 
Survivors 
Warm Challenge 
Survivors 
Neutral FA    
Myristic (14:0) 5.5 ± 0.32 a 5.4 ± 0.02 a 4.3 ± 0.12 b 
Palmitic (16:0) 15.9 ± 0.39 a 12.5 ± 0.27 b 20.4 ± 0.57 c 
Stearic (18:0) 2.2 ± 0.13 ab 1.71 ± 0.07 a 2.4 ± 0.22 b 
Oleic (18:1) 22.8 ± 2.46 a 23.1 ± 2.38 a 13.8 ± 0.37 b 
Vaccenic (18:1) 5.4 ± 0.30 a 5.5  ± 0.22 a 4.2 ± 0.08 ab 
gLinolenic (18:3) 0.3 ± 0.01 a 0.3 ± 0.01 a 0.9 ± 0.03 b 
aLinoleic (18:3) 4.2 ± 0.43 a 4.1 ± 0.24 a 2.7 ± 0.08 b 
Arachidic (20:0) 0.2 ± 0.03 a 0.2 ± 0.02 ab 0.1 ± 0.00 b 
Eicosen (20:1) 2.3 ± 0.96 ab 3.3 ± 0.55 a 0.5 ±  0.25 b 
Eicosad (20:2) 1.3 ± 0.02 a 1.5 ± 0.02 b 0.7 ±  0.03 c 
(20:3n6) 0.4 ± 0.04 a 0.3 ± 0.00 ab 0.2 ± 0.03 b 
Erucic (22:1) 0.8 ± 0.07 a 0.9 ± 0.12 a 0.2 ± 0.01 b 
(21:5n3) 0.33 ± 0.03 a 0.35 ± 0.01 a 0.43 ± 0.02 b 
DPA (22:5) 1.5 ± 0.10 ab 2.0 ± 0.09 b 3.3 ± 0.02 c 
DHA (22:6) 9.2 ± 1.02 a 10.5 ± 0.80 a 19.4 ± 0.63 b 
Nervonic (24:1) 1.4 ± 0.12 a 1.6 ± 0.14 a 0.3 ± 0.03 b 
Polar FA    
Palmitic (16:0) 15.0 ± 0.27 a 12.1 ± 1.83 a 32.5 ± 1.05 b 
Stearic(18:0) 4.3 ± 0.42 a 3.5 ± 0.40 a 9.0 ± 1.35 b 
Oleic(18:1) 8.9 ± 0.85 a 10.5 ± 0.83 a 6.0 ± 0.25 b 
Vaccenic(18:1) 5.5 ± 0.05 a 6.5 ± 0.19 b 2.0 ± 0.09 c 
Linoleic(18:2) 1.7 ± 0.13 a 1.4 ± 0.08 a 0.7 ± 0.04 b 
aLinoleic(18:3) 1.4 ± 0.14 a 1.2 ± 0.07 a 0.3 ± 0.16 b 
Steridonic(18:4) 0.7 ± 0.10 a 0.6 ± 0.07 ab 0.3 ± 0.04 b 
Eicosen(20:1) 2.4 ± 0.33 a 2.9 ± 0.54 a 0.3 ± 0.04 b 
Eicosad(20:2) 2.3 ± 0.18 a 2.4 ± 0.05 a 0.6 ± 0.04 b 
(20:3n6) 0.8 ± 0.06 a 0.5 ± 0.05 ab 0.2 ± 0.08 b 
(20:4n3) 1.8 ± 0.05 a 1.3 ± 0.07 b 0.4 ± 0.02 c 
EPA (20:5) 3.5 ± 0.11 a 3.2 ± 0.05 ab 2.3 ± 0.38 b 
Docosatet (22:4) 1.8 ± 0.29 a 1.3 ± 0.17 ab 0.8 ± 0.05 b 
(22:5n6) 2.8 ± 0.04 a 3.2 ± 0.19a 1.2 ± 0.07 b 
DPA (22:5) 1.9 ± 0.02 a 2.6 ± 0.22 b 1.3 ± 0.07 a 
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Table 4. Statistically significant changes in fatty acid composition (% of 
total fatty acids) of muscle tissue in initial, cold-challenged and warm-
challenged survivors. Data are X  ± SE.  Mean values marked with 
different letters indicate statistically significant differences at p < 0.05. 
 
 
 
 
  
 Initial  Cold Challenge 
Survivor  
Warm Challenge 
Survivor  
Neutral FA    
Eicosen (20:1) 1.9 ± 0.05 a 2.2 ± 0.15 a 0.8 ± 0.41 b 
Polar FA    
Palmitic (16:0) 15.8 ± 1.62 a 16.1 ± 0.40 a 29.0 ± 0.43 b 
Vaccenic(18:1) 4.7 ± 0.47 a 4.3 ± 0.04 a 2.2 ± 0.06 b 
Linoleic(18:2) 2.1 ± 0.27 a 1.8 ± 0.11 a 1.1 ± 0.04 b 
aLinoleic(18:3) 2.0 ± 0.34 a 1.7 ± 0.17 ab 0.7 ± 0.05 b 
Eicosen (20:1) 0.8 ±  0.11 ab 0.8 ± 0.13 a 0.3 ± 0.11 b 
Eicosad (20:2) 0.9 ± 0.06 a 0.9 ± 0.03 a 0.6 ± 0.02 b 
(20:4n3) 1.2 ± 0.04 a 1.2 ± 0.04 a 0.4 ±  0.01 b 
(22:5n6) 3.3 ± 0.12 a 3.5 ± 0.17 a 2.5 ± 0.08 b 
DPA (22:5) 2.8 ± 0.05 a 2.6 ± 0.06 a 1.6 ± 0.05 b 
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Figure 1 – Storage and membrane lipids in alewife gill tissue. Select 
individual fatty acids and fatty acid indices of initial, warm-challenged, 
and cold-challenged fish (survivors only).  Mean values marked with 
different letters indicate statistically significant differences at p < 0.05. 
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Figure 2 - Storage and membrane lipids in alewife liver tissue. 
Select individual fatty acids and fatty acid indices of initial, warm-
challenged, and cold-challenged fish (survivors only).  Mean values 
marked with different letters indicate statistically significant differences 
at p < 0.05. 
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Figure 3 - Storage and membrane lipids in alewife muscle tissue.  
Select individual fatty acids and fatty acid indices of initial, warm-
challenged, and cold-challenged fish (survivors only).  Mean values 
marked with different letters indicate statistically significant differences 
at p < 0.05. 
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Figure 4 -  Storage and membrane lipids in alewife gill tissue from 
survivors and mortalities. Select individual fatty acids and fatty acid 
indices of warm- and cold-challenged survivors and mortalities.  
Asterisks (*) indicate statistically significant differences (p < 0.05) as 
determined using t-tests. 
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Figure 5 – Storage and membrane lipids in alewife liver tissue from 
survivors and mortalities. Select individual fatty acids and fatty acid 
indices of warm- and cold-challenged survivors and mortalities.  
Asterisks (*) indicate statistically significant differences (p < 0.05) as 
determined using t-tests. 
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Figure 6 – Storage and membrane lipids in alewife muscle tissue 
from survivors and mortalities. Select individual fatty acids and fatty 
acid indices of warm- and cold-challenged survivors and mortalities.  
Asterisks (*) indicate statistically significant differences (p < 0.05) as 
determined using t-tests. 
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Appendix A - Sample Preparation and Extraction of Fatty Acids.   
 
Procedure 1: Extraction of Lipids from Tissues 
 
Equipment: 
Brinkman Polytron Homogenizer (~½ inch O.D.)  
Glass Flat Bottom Screw Top Vials (~20 ml capacity) with Teflon lined caps 
15 ml Conical Test tubes with Teflon lined caps 
 
Consumables: 
Chloroform 
Methanol 
Butylated Hydroxytoluene (BHT) 
 
 
Description:  Below is a procedure which allows for reproducible extraction of lipids 
(polar and neutral) from small amounts of tissue.  The procedure is qualitative, but can be 
modified for quantitative recovery.  Briefly, the tissues are homogenized in a solvent, 
after which the lipids are recovered by two applications of chloroform.  The chloroform 
washes are then cleaned further with a low volume application/removal of water.  
Solvents are evaporated, and the recovered lipids are reconstituted and stored in hexane.   
1) Fill a screw-top homogenizer vial with 6 ml of chloroform:methanol (50:50 by 
volume).   Cap vial to prevent loss of solvent to evaporation. 
2) Carefully extract and weigh tissue sample on tared plastic weigh boat (small size).  
150-200 mg is recommended – larger amounts may saturate solvent, and lesser 
amounts may not provide enough fatty acid for analysis.   Should the sample not 
afford 150 mg, Gill samples of less than 100 mg have been successfully extracted 
and analyzed. 
3) Record the weight of the sample and add the tissue to the homogenizer vial. 
4) Homogenize the tissue sample for 1 min at speed 5 in the fume hood.  After 30 
seconds of homogenization, visually inspect the sample, as the sample may need 
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to be capped and shaken to ensure that tissues are suspended in the solvents.  
Between samples, rinse the homogenizer first in chloroform:methanol (50:50) and 
then in methanol.  To prevent sample carry over, wipe the homogenizer with a 
kimwipe and visually inspect for tissue.  Use tweezers to remove any tissue that 
remains on the homogenizer.   Rinse the homogenizer in chloroform:methanol 
(50:50) and then in methanol and wipe dry before storage. 
5) Transfer entire homogenate to a labeled 15 ml round-bottom screw-top test tube 
with a Pasteur pipette.  Flush test tube with nitrogen and seal with Teflon-lined 
screw cap.  Place in centrifuge, balance centrifuge as needed, and spin for 10 min 
at maximum speed (#7).  Visually inspect tube.  Solvents should be free of solids, 
and the tissue should have formed a pellet.   
6) Supernatant Tube - Transfer supernatants to a 15 ml conical test tube, leaving 
tissue residue behind.  
7) Add 3 ml of distilled water to the supernatant tube.  Vortex tubes for 1 min and 
centrifuge again for 10 min at maximum speed.   
8) Organic Wash #1 – With a Pasteur pipette, carefully transfer the lower layer 
(containing the extracted lipids) to a labeled 15ml conical test tube.  To this, add 
10 drops of distilled water with a Pasteur pipette and seal under nitrogen.   
9) Add 3 mls chloroform to the supernatant tube (which still contains MeOH and 
H2O), vortex for 1 min, and centrifuge for 10 min at maximum speed. 
10) Organic Wash #2 - Carefully transfer the lower layer containing the extracted 
lipids to organic wash #1. 
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11) Vortex the organic wash tube for 1 minute as a final purification step (10 drops of 
H2O added at step 8 intended to collect any remaining water soluble 
components).  Centrifuge for 10 min at maximum speed.  Transfer bottom lipid 
containing layer to a 15 ml round bottomed tube, being sure not to carry any of 
the aqueous layer into the round bottomed tube.   
12) Place lipid containing sample tube in warming block, and evaporate the solvent 
with a stream on nitrogen to dryness.  Resuspend the lipids in 0.5 ml hexane.  
Flush the tube with nitrogen and seal with Teflon-lined screw cap. 
13) Store extracted lipids in the freezer or proceed directly to Procedure 2: 
Separation of Neutral and Polar Fractions.   
Technical Notes:  
1) For Qualitative analysis, tissue free transfer of the supernatant (step 6) is more 
important than recovering the majority of the solvents.  If pellet formation is poor, 
spin down for a greater duration or leave a small quantity of solvent on the pellet 
to ensure that no tissue is inadvertently transferred.  Small amounts of tissue 
transferred with the solvent can result in poorly defined organic and aqueous 
phases (large, cloudy interface) and may require discard of the sample.  Should a 
sample not be replaceable, spinning the sample down in centrifuge tube to re-
pellet the transferred tissue is preferable to performing multiple extractions as 
solvent ratios used for extraction are critical.  Should a large interface appear 
immediately following step 7, tissue transfer is a likely cause.   
2) Organic phase transfers in steps 6 and 8 are performed with a Pasteur pipette.  For 
cleaner samples, it is recommended that the pipette be pushed though the interface 
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quickly to prevent mixing of the two phases.  Once through, a gentle press of the 
bulb performed just prior to drawing up the organic (lower) phase will discharge 
any of the upper phase trapped in the pipette.   This technique minimizes any 
phase mixing that may occur during transfer and is of greater importance if 
multiple draws are required to remove the bottom layer. 
3) Scale-up:  If using larger volumes of solvent for larger sample sizes, volume 
ratios throughout the procedure cannot be changed without additional validation 
procedures.  Extractions/separations using these methods are robust using the 
organic/aqueous ratios described, but may not remain consistent should ratios be 
modified in the process of scale-up.     
4) Separatory Funnels – For larger sample sizes, separation of organic/aqueous 
phases may be improved with the use of separatory funnels.  The separation of 
larger volumes in centrifuge tubes may require additional equipment (centrifuge 
and higher capacity tubes), and  and additional equipment to that listed above.  
Separatory funnels allow for easy mixing of solvents and provide a precise 
removal of the organic phase with very little solvent loss.  The use of separatory 
funnels is recommended should a true quantitation of fatty acid content in tissues 
be desired as the organic phase can be almost entirely removed without collecting 
interface or aqueous phase.  However, allot 24 hours to allow a very clean phase 
separation . 
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Appendix B - Separation of Polar and Neutral Fractions  
 
Equipment: 
Rotovap 
Ringstand 
Stainless Steel SPE valve 
250 ml boiling flasks (2 for each sample) 
 
Consumables: 
SPE Column 
Chloroform 
Methanol 
Pasteur Pipettes 
 
Description:  Fatty acids are bound to a glycerol molecule in both the phospholipid 
(polar) and triacylglyceride (neutral) form.  The procedure below allows for the 
separation of polar and neutral lipid fractions using a Solid Phase Extraction Cartridge.   
Briefly, a sample containing both polar and neutral lipids is applied to an SPE cartridge.  
The neutral fraction elutes with the application of chloroform.  The polar fraction, 
collected separately, elutes with the application of methanol.  Solvents are then 
evaporated and the fractions are collected into tubes. 
1) Fill the water bath with deionized water and turn it on (should be done first as it 
takes some time to come to temperature). 
2) Secure a SPE-pack extraction cartridge on a ring stand with the large stem pointed 
upwards.  Attach the stainless steel on-off valve to the bottom of the cartridge.  
Adjust the height of the cartridge to allow a 250 ml boiling flask to fit underneath. 
3) Place a labeled boiling flask under the cartridge, close the valve, and fill the 
cartridge to the base of the stem with chloroform using a Pasteur pipette.  A 
properly “charged” cartridge will appear translucent.  Any air bubbles present in 
the cartridge (white areas) can be removed by eluting approximately 5ml 
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chloroform through the cartridge using the glass syringe designated for 
chloroform (must be done with valve open).   
4) Close valve and add the lipid extract (0.5ml) to the neck of the cartridge using a 
Pasteur pipette, being careful not to overfill.  If sample volume is too large to fit 
into the neck, open the on-off valve briefly to allow the sample to drain into the 
cartridge, and then close the valve again.  Continue filling neck with sample until 
the entire sample is loaded.   At this time, the polar fraction will bind to the 
stationary phase in the column.   
5) Fill a 30 ml glass syringe with 20ml chloroform.  Use a few drops of chloroform 
from the syringe to completely fill the stem of the SPE cartridge to ensure no air 
is remaining in either the syringe luer lock or the SPE cartridge neck.  This is to 
prevent the formation of an air pocket in the cartridge during elution.  Attach the 
30 ml syringe upside-down to the top of the cartridge. 
6) Push the 20ml chloroform evenly through the cartridge over a 1 min period until 
the syringe is empty.  Close the on-off valve at the base of the cartridge and 
remove the syringe. 
7) The flask contains the neutral fraction (storage lipids).  Cap and set aside. 
8) Place a second clean flask underneath the SPE cartridge.   
9) Fill a 30 ml glass syringe with 30ml Methanol.  Use a few drops of methanol from 
the syringe to completely fill the stem of the SPE cartridge to ensure no air is 
remaining in either the syringe luer lock or the SPE cartridge neck.   Attach the 30 
ml syringe upside-down to the top of the cartridge. 
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10) Push the 30ml of methanol evenly through the cartridge over a 1 min period until 
the syringe is empty.  Close the valve at the base of the cartridge and remove the 
syringe. 
11) The flask contains the polar fraction (phospholipids).  Cap and set aside. 
 
Rotovap Drydown 
12) To concentrate the sample, use a Rotovap until the majority of the solvent has 
been completely removed.  Recover the lipid fraction from the flask by using 
three 2 ml rinses of chloroform.  These recoveries should be pooled in a small 
round bottom tube and dried down completely with nitrogen.   
13) Reconstitute the sample in 1 ml Toluene – Store in freezer if derivitization cannot 
be performed immediately. 
 
 
 
Technical Notes:   
1) Overfill of the SPE neck is not a critical issue if doing qualitative fatty acid 
analysis.  Should overfill occur, be sure to adequately rinse the outside of the 
cartridge with chloroform and methanol to prevent transfer of overfill (both polar 
and neutral fractions) to flasks during elution. 
2) As the cartridge is charged with chloroform, the neutral fraction is not bound to 
the stationary phase during sample loading.  If the valve is opened to facilitate 
sample loading, chloroform runoff may contain neutral lipids.  For quantitative 
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analysis, the neutral collection flask should be placed beneath the valve during 
sample loading to collect any neutral lipids eluting prior to the wash sequence. 
3) At step 5, care should be taken not to introduce an air bubble to the cartridge after 
sample loading.  However, if air is present between the cartridge and the syringe 
prior to elution, the sample can be eluted without introducing the air bubble to the 
stationary phase.  Constant pressure on the syringe (vs. erratic) will prevent the air 
bubble from transferring to the SPE column and will ensure appropriate elution of 
the analytes. 
4) BHT content of solvents should be kept low (<0.01%).  The final steps of the 
separation procedure involve a drydown/concentration of the sample.  High BHT 
solvent concentrations, in addition to concentration of BHT in extracts (30ml to 
0.5ml) can lead to very large BHT peaks during GC analysis and will add a 
significant weight contribution (0.5mg or more) should a quantitative recovery be 
performed.  The boiling point of BHT is 265°C.  Therefore, any BHT added 
during separation, extraction, or derivitization is carried through the procedure.      
5) A supply of the solvent used to elute each fraction should be available to rinse the 
neck of the flask after isolating the fractions (prior to removing the flask from the 
base of the SPE column).  Sample may splash on to the flask neck during elution.  
Due to the volatility of the solvents, the sample can adhere to the neck and will 
not be recovered for the next steps should it not be washed down to the base of 
the flask. 
6) SPE cartridges can be used for 6 samples.  Following each sample, the cartridge 
should be rinsed with methanol and chloroform. 
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7) A complete dry down is necessary as water can interfere with the derivitization in 
the next procedure.  
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Appendix C - Derivitization to Fatty Acid Methyl Esters (FAME) 
and Chromatographic Analysis 
 
Equipment: 
Hot water bath or 
Heating plate and glass beaker 
15 ml glass conical tubes (with teflon lined cap) 
Gas Chromatograph with Split Injector (Hewlett-Packard 5890 series II Gas 
Chromatograph) 
Microcapillary column - Restek FAMEWAX Crossbond PEG, 30 meter, 0.25 mm ID 
Flame Ionization Detector 
Data Integrator – Hewlett-Packard 3396 Series III 
Hamilton Syringe capable of 1uL injection 
 
Consumables: 
Pasteur Pipettes 
Methanolic base (0.6N metallic sodium in anhydrous methanol) 
Methyl Acetate 
Glacial Acetic Acid 
Hexane (spike with 23:0 Internal Standard – see Appendix D) 
Double distilled water 
Sodium Sulfate 
Nitrogen  
Chromatographic Grade Helium – Carrier Gas 
 
 
Derivitization of Fatty Acid Fractions to FAME 
1. Prepare a warm water bath (50°C) using a hot water bath or hot plate.  
2. Transfer fatty acid fraction from the round bottom glass tube to a 15 mL glass 
conical tube containing 2 mL of methanolic base (if the sample was frozen for 
storage, see technical notes #1 and #2 below). 
3. Add 1 drop of methyl acetate to the tube, seal under nitrogen, and vortex for 10 
seconds to ensure adequate mixing.   
4. Place the conical tube in the water batch (50°C) for 10 minutes, remove and allow 
to cool for 1 minute.   
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5. Using a Pasteur pipette, add two drops of glacial acetic acid to stop the reaction.  
After vortexing briefly, add 1 mL of hexane and 1 mL of double distilled water.  
Vortex again for 10 seconds to ensure adequate mixing. 
6. Place tube in centrifuge and spin until layers form (can be achieved in less than 1 
minute).  Using a pasteur pipette, transfer the bottom (aqueous) layer to a second, 
properly labeled 15 mL glass conical tube.   
7. To the second tube containing the bottom layer of the sample, add 1 mL of 
hexane.  Vortex briefly and centrifuge to form layers.  Using a Pasteur pipette, 
remove the top layer and add it to the initial sample (top layer only – see 
Technical Note #3).  
8. Briefly spin the 15 mL conical sample tube which now contains the top layer of 
the initial sample prep, and the top layer of the sample ‘wash’.  Should any water 
be visible in the bottom of the tube, remove with a pasteur pipette. 
9. Add approximately 30 mg of sodium sulfate to the sample tube. 
10.  Place tube in a warming block (low heat) and dry down under a stream of 
nitrogen until the sample volume is approximately 100 uL or less.   
11. Transfer sample to a pre-weighed, sealable glass vial, and continue to dry down 
under a stream of nitrogen for approximately 10 minutes to remove any remaining 
volatile solvent.  See Technical Note #4. 
12. After final drydown, record sample weight.  To the sample vial, add 
approximately 35 uL of hexane for each mg of FAME recovered (see Technical 
Note #5).   Hexane used for sample reconstitution should be spiked with Internal 
Standard (synthetic FAME 23:0) present at a concentration of 0.25 ug/ul.     
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Chromatographic Analysis 
13.  If the sample was stored in the freezer, allow sample to come to room 
temperature prior to injection (keep sample capped during thaw to prevent 
formation of condensate in the sample). 
14. Remove sample cap and draw approximately 2uL of sample into an appropriate 
glass Hamilton syringe.  Draw sample and replace vial cap immediately to 
minimize hexane evaporation from sample (evaporation causes sample 
concentration and can result in FID signals outside the limits of detection). 
15. Holding the syringe with the plunger down, tap gently on the barrel of the syringe 
until all air bubbles have travelled to the base of the needle.  In a fume hood with 
gloved hands, dispense sample as necessary to remove air trapped in the syringe.   
16. Inject 1 uL of sample in the GC for analysis using the following chromatographic 
parameters. 
Injector temperature: 130° C 
Detector temperature: 230° C 
Initial column temperature : 130° C 
Temperature ramp : 6 deg/min for 15 minutes, followed by a 15 minute hold 
Split ratio : 10:1 
Carrier Gas: Helium 
 
17. Following analysis, ensure that all peaks of interest are within detection limits 
using the areas generated by the integrator (peaks which have been cut off by the 
integrator may still be within detection limits.) 
18. If peaks of interest are not within detection limits, concentrate or dilute the sample 
with Hexane as necessary to provide an acceptable analysis. 
19.  Samples can be frozen for storage.   
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Technical Notes: 
  
1. Wherever possible, the derivitization of the fatty acid fractions to FAME should 
be performed as soon as possible following fraction collections.  FAME are more 
stable than their non-derivitized fatty acid precursors and therefore can be stored 
with greater confidence for extended periods.   
2. Should fatty acid fractions suspended in toluene be frozen prior to derivitization, 
allow the round bottom tube to come to room temperature while still capped. This 
minimizes/prevents the formation of condensate which can interfere with 
methanolysis. 
3. During separation of layers following methanolysis, water is added as a solvent to 
help separate and remove impurities from the FAME.  When the initial separation 
is performed, the removal of the bottom (aqueous) layer procedure should be 
performed such that none of the bottom layer is left in the conical sample tube.  
This may require some incorporation of the upper layer in the aliquot.  The 
second extraction performed on the ‘wash’ (steps 6 and 7 above) will recover any 
FAME lost during this initial transfer.  Following this procedure will provide 
cleaner samples with minimal loss of FAME. 
4. Weighing the final FAME yield is useful for determining the appropriate amount 
of solvent needed for sample reconstitution.  An overly concentrated sample may 
require multiple injections/dilution before an acceptable analysis is achieved.  
This is a time consuming process but be avoided by taking the time to determine 
the amount of FAME recovered following derivitization.  Furthermore, glassware 
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contamination, solvent contamination, SEP cartridge failure, fraction 
misidentification, poor derivitization, etc. can result in faulty sample preparations 
which may not be recognized even after GC analysis.  By weighing the absolute 
recovery of FAME, which adds little time to the procedure, faulty extractions 
have a better chance to be identified.   
5. The ratio of FAME to Hexane used to reconstitute samples for GC analysis 
provided chromatography within detection limits for the majority of samples 
prepared for this study.  However, due to the volatility of hexane and the 
differences in sample weights, dilution or concentration of preparations was 
occasionally required.  Though the amount of FAME that is delivered to the 
column is inherently inconsistent due to the use of the split injector, FAME 
recoveries from similar sample sizes should remain fairly consistent in all steps 
upstream of the chromatographic injection.  The 35 uL to 1 mg ratio is a 
recommendation but may need to be modified due to differences in 
reproducibility of sample delivery.   
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APPENDIX D – Chromatogram and Approximate Retention Time 
of Individual Fatty Acids 
 
 
 
Calibration standard (33 commonly occurring fatty acids) analyzed with 
Restek FAMEWAX Crossbond microcapillary column using the separation 
method described above. Fatty Acid 23:0 (Retention Time ~24.7 min) is the 
Internal Standard. 
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APPENDIX E – Raw Data for All GC Runs 
 
The following tables include raw data from the chromatographic runs of all tissues used 
in the above described research effort.  For each test group, tissue, and fraction below, 
data from 33 fatty acids are reported (where detected) as a percentage of total sample 
fatty acid content.  These fatty acid signatures have been adjusted using measured 
response factors and normalized within each analysis against an internal standard as 
described in the Methods section (Gas Chromatography) above.  Data presented include 
the triplicate runs used for each sample point, means, standard errors, and a summary of 
Fatty Acid Indices for each particular data set, where: 
 
Saturated Fatty Acids (Saturates) : 14:0, 16:0, 18:0, 20:0, 22:0, 24:0 
Monounsaturated Fatty Acids (Monoenes): 14:1, 16:1, 18:1, 20:1, 22:1, 24:1 
Polyunsaturated Fatty Acids (PUFA): 16:2n4, 16:3n4, 16:4n1, 18:3, 18:4, 18:4n1, 20:2, 
20:3n6, 20:4, 20:3, 20:4n3, 20:5, 21:5n3, 22:4, 
22:5n6, 22:5, 22:6 
n6 (all n6 fatty acids): 18:2, 18:3 (γ-Linolenic), 20:2, 20:3n6, 20:4, 22:4, 22:5n6 
n3 (all n3 fatty acids):  18:3 (α-Linolenic), 18:4, 20:4n3, 20:5, 21:5n3, 22:5, 22:6 
n3 HUFA (Highly unsaturated n3 fatty acids): 20:4n3, 20:5, 21:5n3, 22:5, 22:6 
n3/n6 ratio : % n3 ÷ % n6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test Group Page Test Group Raw Data Page  
Initial Gill Neutral 77 Warm Survivor Liver Polar 92 
Initial Gill Polar 78 Warm Survivor Muscle Neutral93 
Initial Liver Neutral 79 Warm Survivor Muscle Polar 94 
Initial Liver Polar 80 Cold Mort Gill Neutral 95 
Initial Muscle Neutral 81 Cold Mort Gill Polar 96 
Initial Muscle Polar 82 Cold Mort Liver Neutral 97 
Cold Survivor Gill Neutral 83 Cold Mort Liver Polar 98 
Cold Survivor Gill Polar 84 Cold Mort Muscle Neutral 99 
Cold Survivor Liver Neutral 85 Cold Mort Muscle Polar 100 
Cold Survivor Liver Polar 86 Warm Mort Gill Neutral 101 
Cold Survivor Muscle Neutral 87 Warm Mort Gill Polar 102 
Cold Survivor Muscle Polar 88 Warm Mort Liver Neutral 103 
Warm Survivor Gill Neutral 89 Warm Mort Liver Polar 104 
Warm Survivor Gill Polar 90 Warm Mort Muscle Neutral 105 
Warm Survivor Liver Neutral 91 Warm Mort Muscle Polar 106 
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Treatment : Initial 
Tissue: Gill 
Fraction: Neutral 
 
Name 
1=Run 
148 
2=Run 
180 
3=Run 
236   Mean SE 
              
Myristic(14:0) 6.00 5.69 5.75   5.8 0.09 
Myristolic(14:1) 0.00 0.00 0.11   0.0 0.04 
Palmitic(16:0) 17.11 17.41 17.46   17.3 0.11 
Palmitol(16:1) 7.60 7.40 7.62   7.5 0.07 
(16:2n4) 0.46 0.50 0.56   0.5 0.03 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.74 0.40 0.43   0.5 0.11 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 2.37 2.01 2.15   2.2 0.11 
Oleic(18:1) 17.27 18.37 17.87   17.8 0.32 
Vaccenic(18:1) 4.45 4.53 4.20   4.4 0.10 
Linoleic(18:2) 4.44 4.18 4.42   4.3 0.08 
gLinolen(18:3) 0.36 0.37 0.09   0.3 0.09 
(18:3n4) 0.00 0.00 0.10   0.0 0.03 
aLinolen(18:3) 5.28 5.18 5.85   5.4 0.21 
Stearidon(18:4) 2.85 3.10 3.59   3.2 0.22 
(18:4n1) 0.00 0.22 0.20   0.1 0.07 
Arachidic(20:0) 0.47 0.37 0.46   0.4 0.03 
Eicosen(20:1) 2.03 2.03 0.37   1.5 0.55 
Eicosad(20:2) 1.12 1.04 0.98   1.0 0.04 
(20:3n6) 0.48 0.31 0.34   0.4 0.05 
Arachidon(20:4) 3.02 2.70 2.81   2.8 0.09 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.86 2.07 2.18   2.0 0.09 
EPA(20:5) 7.48 7.03 7.37   7.3 0.14 
Behenic(22:0) 0.00 0.15 0.18   0.1 0.06 
Erucic(22:1) 0.47 0.38 0.38   0.4 0.03 
(21:5n3) 0.36 0.34 0.39   0.4 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.95 0.77 0.92   0.9 0.06 
(22:5n6) 1.75 1.26 1.40   1.5 0.15 
DPA(22:5) 2.19 2.00 2.32   2.2 0.09 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 8.26 9.45 8.80   8.8 0.34 
Nervonic(24:1) 0.63 0.72 0.69   0.7 0.03 
Fatty Acid Indices 
Saturates 25.9 25.6 26.0   25.9 0.11 
Monoenes 32.4 33.4 31.2   32.4 0.63 
PUFA 41.6 40.9 42.8   41.8 0.53 
n6 12.1 10.6 11.0   11.2 0.46 
n3 28.3 29.2 30.5   29.3 0.64 
n3 HUFA 20.2 20.9 21.1   20.7 0.28 
n3/n6 2.3 2.7 2.8   2.6 0.14 
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Treatment : Initial 
Tissue: Gill 
Fraction: Polar 
 
Name 
1=Run 
168 
2=Run 
182 
3=Run 
238   Mean SE 
              
Myristic(14:0) 1.99 2.88 3.61   2.8 0.47 
Myristolic(14:1) 1.67 0.00 0.00   0.6 0.56 
Palmitic(16:0) 28.02 29.26 26.35   27.9 0.84 
Palmitol(16:1) 2.03 2.41 3.27   2.6 0.37 
(16:2n4) 0.96 1.11 0.78   1.0 0.10 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.56 0.44 0.56   0.5 0.04 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 10.64 11.62 9.39   10.6 0.64 
Oleic(18:1) 14.41 10.76 11.26   12.1 1.14 
Vaccenic(18:1) 4.70 5.63 4.89   5.1 0.29 
Linoleic(18:2) 1.45 1.25 1.62   1.4 0.11 
gLinolen(18:3) 0.00 0.00 0.29   0.1 0.10 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 0.83 0.84 1.36   1.0 0.18 
Stearidon(18:4) 0.00 0.40 0.67   0.4 0.19 
(18:4n1) 0.00 0.00 0.41   0.1 0.14 
Arachidic(20:0) 1.14 0.64 0.70   0.8 0.16 
Eicosen(20:1) 0.99 0.73 1.08   0.9 0.11 
Eicosad(20:2) 0.68 0.63 0.75   0.7 0.03 
(20:3n6) 0.00 0.00 0.21   0.1 0.07 
Arachidon(20:4) 5.52 4.90 4.43   4.9 0.32 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.00 0.45 0.60   0.4 0.18 
EPA(20:5) 3.01 3.60 3.83   3.5 0.24 
Behenic(22:0) 0.00 0.00 0.00   0.0 0.00 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.00 0.00   0.0 0.00 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 2.06 1.21 1.33   1.5 0.27 
(22:5n6) 1.95 2.23 2.10   2.1 0.08 
DPA(22:5) 1.24 1.04 1.38   1.2 0.10 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 16.15 17.96 18.49   17.5 0.71 
Nervonic(24:1) 0.00 0.00 0.62   0.2 0.21 
Fatty Acid Indices 
Saturates 41.8 44.4 40.1   42.1 1.26 
Monoenes 23.8 19.5 21.1   21.5 1.24 
PUFA 34.4 36.1 38.8   36.4 1.28 
n6 11.7 10.2 10.7   10.9 0.42 
n3 21.2 24.3 26.3   24.0 1.48 
n3 HUFA 20.4 23.0 24.3   22.6 1.15 
n3/n6 1.8 2.4 2.5   2.2 0.20 
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Treatment : Initial 
Tissue: Liver 
Fraction: Neutral 
 
Name 
Run 
151 
Run 
226 
Run 
243   Mean SE 
              
Myristic(14:0) 4.82 5.87 5.69   5.5 0.32 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 15.16 16.23 16.41   15.9 0.39 
Palmitol(16:1) 6.84 6.13 7.07   6.7 0.28 
(16:2n4) 0.40 0.43 0.47   0.4 0.02 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.46 0.50 0.35   0.4 0.04 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 2.37 1.96 2.34   2.2 0.13 
Oleic(18:1) 19.79 27.67 20.93   22.8 2.46 
Vaccenic(18:1) 5.58 5.87 4.87   5.4 0.30 
Linoleic(18:2) 3.58 3.19 3.83   3.5 0.19 
gLinolen(18:3) 0.33 0.30 0.33   0.3 0.01 
(18:3n4) 0.00 0.17 0.00   0.1 0.06 
aLinolen(18:3) 4.15 3.47 4.97   4.2 0.43 
Stearidon(18:4) 2.49 2.18 2.97   2.5 0.23 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.25 0.18 0.28   0.2 0.03 
Eicosen(20:1) 2.93 0.36 3.49   2.3 0.96 
Eicosad(20:2) 1.29 1.28 1.22   1.3 0.02 
(20:3n6) 0.40 0.38 0.28   0.4 0.04 
Arachidon(20:4) 2.57 1.86 2.14   2.2 0.21 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 2.09 1.62 1.74   1.8 0.14 
EPA(20:5) 5.59 4.31 5.65   5.2 0.44 
Behenic(22:0) 0.00 0.55 0.17   0.2 0.16 
Erucic(22:1) 0.72 0.94 0.81   0.8 0.07 
(21:5n3) 0.38 0.28 0.35   0.3 0.03 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.91 1.26 1.22   1.5 0.22 
(22:5n6) 1.81 1.49 1.52   1.6 0.10 
DPA(22:5) 1.56 1.34 1.69   1.5 0.10 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 11.24 8.49 7.95   9.2 1.02 
Nervonic(24:1) 1.32 1.66 1.28   1.4 0.12 
Fatty Acid Indices 
Saturates 22.6 24.8 24.9   24.1 0.75 
Monoenes 37.2 42.6 38.4   39.4 1.65 
PUFA 40.2 32.6 36.7   36.5 2.21 
n6 11.9 9.8 10.5   10.7 0.62 
n3 27.5 21.7 25.3   24.8 1.69 
n3 HUFA 20.9 16.1 17.4   18.1 1.43 
n3/n6 2.3 2.2 2.4   2.3 0.05 
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Treatment: Initial 
Tissue: Liver 
Fraction: Polar 
 
Name 
1=Run 
152 
2=Run 
189 
3=Run 
249   Mean SE 
              
Myristic(14:0) 1.69 2.58 2.89   2.4 0.36 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 14.90 14.53 15.47   15.0 0.27 
Palmitol(16:1) 1.72 2.34 2.76   2.3 0.30 
(16:2n4) 0.00 0.69 0.61   0.4 0.22 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.00 0.28 0.23   0.2 0.09 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 4.80 3.42 4.51   4.2 0.42 
Oleic(18:1) 7.21 9.54 9.93   8.9 0.85 
Vaccenic(18:1) 5.43 5.39 5.57   5.5 0.05 
Linoleic(18:2) 1.46 1.59 1.90   1.7 0.13 
gLinolen(18:3) 0.00 0.10 0.00   0.0 0.03 
(18:3n4) 0.00 0.21 0.00   0.1 0.07 
aLinolen(18:3) 1.18 1.34 1.64   1.4 0.14 
Stearidon(18:4) 0.48 0.67 0.81   0.7 0.10 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.00 0.17 0.28   0.1 0.08 
Eicosen(20:1) 2.01 2.03 3.02   2.4 0.33 
Eicosad(20:2) 2.52 1.99 2.52   2.3 0.18 
(20:3n6) 0.87 0.68 0.80   0.8 0.06 
Arachidon(20:4) 5.56 3.57 3.30   4.1 0.71 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.88 1.71 1.76   1.8 0.05 
EPA(20:5) 3.30 3.66 3.38   3.4 0.11 
Behenic(22:0) 1.83 0.00 0.00   0.6 0.61 
Erucic(22:1) 0.00 0.18 0.23   0.1 0.07 
(21:5n3) 0.00 0.15 0.00   0.1 0.05 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 2.39 1.45 1.58   1.8 0.29 
(22:5n6) 2.78 2.78 2.91   2.8 0.04 
DPA(22:5) 1.84 1.84 1.88   1.9 0.02 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 36.16 36.64 31.44   34.7 1.66 
Nervonic(24:1) 0.00 0.48 0.58   0.4 0.18 
Fatty Acid Indices 
Saturates 23.2 20.7 23.2   22.4 0.83 
Monoenes 16.4 20.0 22.1   19.5 1.67 
PUFA 60.4 59.3 54.8   58.2 1.73 
n6 15.6 12.2 13.0   13.6 1.03 
n3 44.8 46.0 40.9   43.9 1.54 
n3 HUFA 43.2 44.0 38.5   41.9 1.72 
n3/n6 2.9 3.8 3.1   3.3 0.27 
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Treatment: Initial 
Tissue: Muscle 
Fraction: Neutral 
 
Name 
1=Run 
153 
2=Run 
183 
3=Run 
241   Mean SE 
              
Myristic(14:0) 6.20 6.12 5.91   6.1 0.09 
Myristolic(14:1) 0.09 0.00 0.11   0.1 0.03 
Palmitic(16:0) 17.35 18.09 17.21   17.5 0.27 
Palmitol(16:1) 8.53 8.05 7.57   8.0 0.28 
(16:2n4) 0.46 0.45 0.46   0.5 0.00 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.40 0.37 0.39   0.4 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.76 1.84 2.19   1.9 0.13 
Oleic(18:1) 17.10 18.56 19.18   18.3 0.62 
Vaccenic(18:1) 4.57 4.43 3.84   4.3 0.22 
Linoleic(18:2) 4.56 4.32 4.60   4.5 0.09 
gLinolen(18:3) 0.07 0.38 0.07   0.2 0.10 
(18:3n4) 0.11 0.00 0.10   0.1 0.03 
aLinolen(18:3) 6.10 5.69 6.21   6.0 0.16 
Stearidon(18:4) 3.72 3.63 3.90   3.7 0.08 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.26 0.25 0.30   0.3 0.02 
Eicosen(20:1) 1.91 2.02 1.85   1.9 0.05 
Eicosad(20:2) 1.25 1.10 0.94   1.1 0.09 
(20:3n6) 0.27 0.30 0.31   0.3 0.01 
Arachidon(20:4) 2.43 2.26 2.64   2.4 0.11 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.93 2.04 2.08   2.0 0.04 
EPA(20:5) 8.32 7.54 7.41   7.8 0.28 
Behenic(22:0) 0.20 0.00 0.17   0.1 0.06 
Erucic(22:1) 0.41 0.38 0.39   0.4 0.01 
(21:5n3) 0.41 0.37 0.39   0.4 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.49 0.41 0.52   0.5 0.03 
(22:5n6) 1.28 1.28 1.27   1.3 0.00 
DPA(22:5) 1.75 1.70 2.04   1.8 0.11 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 7.59 7.95 7.39   7.6 0.16 
Nervonic(24:1) 0.46 0.50 0.56   0.5 0.03 
Fatty Acid Indices 
Saturates 25.8 26.3 25.8   26.0 0.18 
Monoenes 33.1 33.9 33.5   33.5 0.25 
PUFA 41.2 39.8 40.7   40.6 0.41 
n6 10.4 10.0 10.4   10.3 0.11 
n3 29.8 28.9 29.4   29.4 0.26 
n3 HUFA 20.0 19.6 19.3   19.6 0.20 
n3/n6 2.9 2.9 2.8   2.9 0.01 
82 
 
 
Treatment: Initial 
Tissue: Muscle 
Fraction: Polar 
 
Name 
1=Run 
157 
2=Run 
185 
3=Run 
242   Mean SE 
              
Myristic(14:0) 1.27 0.98 1.70   1.3 0.21 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 18.92 14.83 13.56   15.8 1.62 
Palmitol(16:1) 1.90 1.22 2.56   1.9 0.39 
(16:2n4) 0.00 0.28 0.47   0.3 0.14 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.00 0.21 0.29   0.2 0.09 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 7.33 5.79 6.13   6.4 0.47 
Oleic(18:1) 8.20 5.92 9.02   7.7 0.93 
Vaccenic(18:1) 4.23 4.18 5.60   4.7 0.47 
Linoleic(18:2) 2.00 1.62 2.56   2.1 0.27 
gLinolen(18:3) 0.00 0.00 0.00   0.0 0.00 
(18:3n4) 0.00 0.11 0.00   0.0 0.04 
aLinolen(18:3) 1.86 1.48 2.63   2.0 0.34 
Stearidon(18:4) 0.82 0.49 1.18   0.8 0.20 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.00 0.00 0.00   0.0 0.00 
Eicosen(20:1) 0.76 0.60 0.98   0.8 0.11 
Eicosad(20:2) 0.88 0.84 1.05   0.9 0.06 
(20:3n6) 0.00 0.33 0.52   0.3 0.15 
Arachidon(20:4) 6.98 5.79 5.69   6.1 0.41 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.17 1.27 1.28   1.2 0.04 
EPA(20:5) 6.81 5.98 5.73   6.2 0.33 
Behenic(22:0) 0.00 0.00 0.71   0.2 0.24 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.33 0.26   0.2 0.10 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.74 0.60 0.94   0.8 0.10 
(22:5n6) 3.11 3.51 3.20   3.3 0.12 
DPA(22:5) 2.70 2.86 2.74   2.8 0.05 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 30.31 40.79 31.22   34.1 3.35 
Nervonic(24:1) 0.00 0.00 0.00   0.0 0.00 
Fatty Acid Indices 
Saturates 27.5 21.6 22.1   23.7 1.90 
Monoenes 15.1 11.9 18.2   15.1 1.80 
PUFA 57.4 66.5 59.7   61.2 2.72 
n6 13.7 12.7 13.9   13.4 0.39 
n3 43.7 53.2 45.0   47.3 2.97 
n3 HUFA 41.0 51.2 41.2   44.5 3.37 
n3/n6 3.2 4.2 3.2   3.5 0.33 
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Treatment: Cold Survivors 
Tissue: Gill 
Fraction: Neutral 
 
Name 
1=Run 
159 
2=Run 
193 
3=Run 
247   Mean SE 
              
Myristic(14:0) 5.52 5.69 5.65   5.6 0.05 
Myristolic(14:1) 0.00 0.08 0.09   0.1 0.03 
Palmitic(16:0) 17.18 16.62 17.12   17.0 0.18 
Palmitol(16:1) 7.39 7.58 7.82   7.6 0.13 
(16:2n4) 0.49 0.58 0.52   0.5 0.03 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.42 0.40 0.43   0.4 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 2.12 2.18 1.99   2.1 0.05 
Oleic(18:1) 18.32 15.31 18.99   17.5 1.13 
Vaccenic(18:1) 4.52 4.48 4.41   4.5 0.03 
Linoleic(18:2) 4.17 4.55 4.36   4.4 0.11 
gLinolen(18:3) 0.36 0.37 0.09   0.3 0.09 
(18:3n4) 0.00 0.09 0.11   0.1 0.03 
aLinolen(18:3) 4.89 5.53 5.14   5.2 0.19 
Stearidon(18:4) 2.86 3.27 3.03   3.1 0.12 
(18:4n1) 0.00 0.09 0.24   0.1 0.07 
Arachidic(20:0) 0.46 0.43 0.44   0.4 0.01 
Eicosen(20:1) 2.32 1.94 0.38   1.5 0.59 
Eicosad(20:2) 1.12 1.22 1.16   1.2 0.03 
(20:3n6) 0.43 0.28 0.33   0.3 0.04 
Arachidon(20:4) 2.88 3.09 2.78   2.9 0.09 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.93 1.92 1.98   1.9 0.02 
EPA(20:5) 7.38 8.67 7.40   7.8 0.43 
Behenic(22:0) 0.17 0.14 0.15   0.2 0.01 
Erucic(22:1) 0.45 0.39 0.46   0.4 0.02 
(21:5n3) 0.38 0.40 0.37   0.4 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.84 0.78 0.68   0.8 0.05 
(22:5n6) 1.41 1.48 1.49   1.5 0.03 
DPA(22:5) 2.19 2.19 2.15   2.2 0.02 
Lignocer(24:0) 0.00 0.00 0.08   0.0 0.03 
DHA(22:6) 8.99 9.71 9.29   9.3 0.21 
Nervonic(24:1) 0.80 0.55 0.87   0.7 0.10 
Fatty Acid Indices 
Saturates 25.5 25.1 25.4   25.3 0.13 
Monoenes 33.8 30.3 33.0   32.4 1.05 
PUFA 40.7 44.6 41.5   42.3 1.18 
n6 11.2 11.8 10.9   11.3 0.26 
n3 28.6 31.7 29.3   29.9 0.92 
n3 HUFA 20.9 22.9 21.2   21.6 0.63 
n3/n6 2.6 2.7 2.7   2.7 0.05 
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Treatment: Cold Survivors 
Tissue: Gill 
Fraction: Polar 
 
Name 
1=Run 
169 
2=Run 
196 
3=Run 
248   Mean SE 
              
Myristic(14:0) 2.48 2.09 2.32   2.3 0.12 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 23.57 20.85 21.93   22.1 0.79 
Palmitol(16:1) 1.84 2.23 2.11   2.1 0.11 
(16:2n4) 1.05 1.26 1.04   1.1 0.07 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.51 0.62 0.61   0.6 0.03 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 9.25 8.37 9.15   8.9 0.28 
Oleic(18:1) 10.43 10.63 10.31   10.5 0.09 
Vaccenic(18:1) 6.20 6.21 6.11   6.2 0.03 
Linoleic(18:2) 1.23 1.53 1.24   1.3 0.10 
gLinolen(18:3) 0.00 0.28 0.27   0.2 0.09 
(18:3n4) 0.00 0.12 0.00   0.0 0.04 
aLinolen(18:3) 0.76 1.09 0.96   0.9 0.10 
Stearidon(18:4) 0.00 0.53 0.48   0.3 0.17 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.63 0.66 0.75   0.7 0.04 
Eicosen(20:1) 0.93 0.84 1.20   1.0 0.11 
Eicosad(20:2) 0.72 0.73 0.73   0.7 0.00 
(20:3n6) 0.00 0.16 0.30   0.2 0.09 
Arachidon(20:4) 6.46 6.32 5.95   6.2 0.15 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.60 0.63 0.55   0.6 0.02 
EPA(20:5) 4.67 4.73 3.93   4.4 0.26 
Behenic(22:0) 0.00 0.00 0.92   0.3 0.31 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.00 0.11   0.0 0.04 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.71 1.90 1.88   1.8 0.06 
(22:5n6) 2.95 2.90 3.07   3.0 0.05 
DPA(22:5) 1.52 1.54 1.43   1.5 0.03 
Lignocer(24:0) 0.00 0.30 0.00   0.1 0.10 
DHA(22:6) 22.48 23.00 21.96   22.5 0.30 
Nervonic(24:1) 0.00 0.49 0.70   0.4 0.21 
Fatty Acid Indices 
Saturates 35.9 32.3 35.1   34.4 1.10 
Monoenes 19.4 20.4 20.4   20.1 0.34 
PUFA 44.7 47.3 44.5   45.5 0.92 
n6 13.1 13.8 13.4   13.4 0.22 
n3 30.0 31.5 29.4   30.3 0.62 
n3 HUFA 29.3 29.9 28.0   29.0 0.57 
n3/n6 2.3 2.3 2.2   2.3 0.03 
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Treatment: Cold Survivors 
Tissue: Liver 
Fraction: Neutral 
 
Name 
1=Run 
163 
2=Run 
198 
3=Run 
252   Mean SE 
              
Myristic(14:0) 5.46 5.41 5.37   5.4 0.02 
Myristolic(14:1) 0.00 0.00 0.08   0.0 0.03 
Palmitic(16:0) 12.81 12.77 11.98   12.5 0.27 
Palmitol(16:1) 6.95 7.62 6.61   7.1 0.30 
(16:2n4) 0.46 0.52 0.43   0.5 0.03 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.47 0.48 0.48   0.5 0.00 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.78 1.78 1.58   1.7 0.07 
Oleic(18:1) 21.46 20.05 27.78   23.1 2.38 
Vaccenic(18:1) 5.73 5.69 5.06   5.5 0.22 
Linoleic(18:2) 3.48 3.88 3.21   3.5 0.20 
gLinolen(18:3) 0.30 0.31 0.28   0.3 0.01 
(18:3n4) 0.15 0.12 0.11   0.1 0.01 
aLinolen(18:3) 4.01 4.50 3.66   4.1 0.24 
Stearidon(18:4) 2.55 2.88 2.21   2.5 0.20 
(18:4n1) 0.00 0.11 0.00   0.0 0.04 
Arachidic(20:0) 0.19 0.19 0.14   0.2 0.02 
Eicosen(20:1) 3.17 2.48 4.35   3.3 0.55 
Eicosad(20:2) 1.49 1.46 1.43   1.5 0.02 
(20:3n6) 0.27 0.27 0.26   0.3 0.00 
Arachidon(20:4) 2.23 2.39 1.77   2.1 0.18 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.68 1.76 1.47   1.6 0.09 
EPA(20:5) 5.36 6.15 4.66   5.4 0.43 
Behenic(22:0) 0.25 0.00 0.07   0.1 0.07 
Erucic(22:1) 0.85 0.70 1.12   0.9 0.12 
(21:5n3) 0.33 0.37 0.34   0.3 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.26 1.43 1.32   1.3 0.05 
(22:5n6) 2.10 2.05 1.67   1.9 0.14 
DPA(22:5) 2.19 2.03 1.87   2.0 0.09 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 11.38 11.31 8.94   10.5 0.80 
Nervonic(24:1) 1.65 1.28 1.75   1.6 0.14 
Fatty Acid Indices 
Saturates 20.5 20.1 19.1   19.9 0.40 
Monoenes 39.8 37.8 46.8   41.5 2.71 
PUFA 39.7 42.0 34.1   38.6 2.35 
n6 11.1 11.8 9.9   11.0 0.54 
n3 27.5 29.0 23.1   26.6 1.76 
n3 HUFA 20.9 21.6 17.3   19.9 1.35 
n3/n6 2.5 2.5 2.3   2.4 0.05 
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Treatment: Cold Survivors 
Tissue: Liver 
Fraction: Polar 
 
Name 
1=Run 
164 
2=Run 
201 
3=Run 
253   Mean SE 
              
Myristic(14:0) 1.12 1.67 2.03   1.6 0.26 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 8.48 13.35 14.42   12.1 1.83 
Palmitol(16:1) 1.68 2.10 2.39   2.1 0.21 
(16:2n4) 0.64 0.69 0.56   0.6 0.04 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.22 0.24 0.29   0.2 0.02 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 2.67 3.89 3.87   3.5 0.40 
Oleic(18:1) 9.96 9.43 12.13   10.5 0.83 
Vaccenic(18:1) 6.33 6.87 6.30   6.5 0.19 
Linoleic(18:2) 1.25 1.52 1.42   1.4 0.08 
gLinolen(18:3) 0.00 0.14 0.16   0.1 0.05 
(18:3n4) 0.27 0.29 0.25   0.3 0.01 
aLinolen(18:3) 1.09 1.34 1.25   1.2 0.07 
Stearidon(18:4) 0.45 0.64 0.68   0.6 0.07 
(18:4n1) 0.00 0.00 0.41   0.1 0.14 
Arachidic(20:0) 0.15 0.21 0.42   0.3 0.08 
Eicosen(20:1) 2.58 2.23 3.99   2.9 0.54 
Eicosad(20:2) 2.30 2.48 2.38   2.4 0.05 
(20:3n6) 0.50 0.35 0.53   0.5 0.05 
Arachidon(20:4) 4.64 3.31 2.83   3.6 0.54 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.37 1.38 1.16   1.3 0.07 
EPA(20:5) 3.20 3.06 3.22   3.2 0.05 
Behenic(22:0) 0.56 0.00 0.25   0.3 0.16 
Erucic(22:1) 0.18 0.22 0.32   0.2 0.04 
(21:5n3) 0.00 0.00 0.13   0.0 0.04 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.34 1.58 1.00   1.3 0.17 
(22:5n6) 3.55 3.07 2.93   3.2 0.19 
DPA(22:5) 3.08 2.38 2.43   2.6 0.22 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 42.02 37.05 31.57   36.9 3.02 
Nervonic(24:1) 0.37 0.51 0.68   0.5 0.09 
Fatty Acid Indices 
Saturates 13.0 19.1 21.0   17.7 2.42 
Monoenes 21.1 21.4 25.8   22.8 1.53 
PUFA 65.9 59.5 53.2   59.5 3.67 
n6 13.6 12.5 11.2   12.4 0.67 
n3 51.2 45.8 40.4   45.8 3.11 
n3 HUFA 49.7 43.9 38.5   44.0 3.22 
n3/n6 3.8 3.7 3.6   3.7 0.05 
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Treatment: Cold Survivors 
Tissue: Muscle 
Fraction: Neutral 
 
Name 
1=Run 
161 
2=Run 
195 
3=Run 
250   Mean SE 
              
Myristic(14:0) 6.04 6.13 5.61   5.9 0.16 
Myristolic(14:1) 0.10 0.00 0.00   0.0 0.03 
Palmitic(16:0) 16.92 17.04 17.24   17.1 0.09 
Palmitol(16:1) 8.22 8.64 7.45   8.1 0.35 
(16:2n4) 0.44 0.51 0.42   0.5 0.03 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.41 0.37 0.40   0.4 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.76 1.71 1.95   1.8 0.07 
Oleic(18:1) 18.82 16.23 18.86   18.0 0.87 
Vaccenic(18:1) 4.46 4.55 4.31   4.4 0.07 
Linoleic(18:2) 4.34 4.58 4.05   4.3 0.15 
gLinolen(18:3) 0.41 0.39 0.37   0.4 0.01 
(18:3n4) 0.10 0.19 0.18   0.2 0.03 
aLinolen(18:3) 5.51 5.68 5.04   5.4 0.19 
Stearidon(18:4) 3.69 3.75 3.21   3.6 0.17 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.28 0.26 0.28   0.3 0.01 
Eicosen(20:1) 2.22 1.95 2.49   2.2 0.15 
Eicosad(20:2) 1.20 1.28 1.13   1.2 0.04 
(20:3n6) 0.31 0.26 0.29   0.3 0.01 
Arachidon(20:4) 2.33 2.55 2.55   2.5 0.07 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.91 1.84 1.91   1.9 0.02 
EPA(20:5) 8.07 8.47 7.27   7.9 0.35 
Behenic(22:0) 0.16 0.00 0.00   0.1 0.05 
Erucic(22:1) 0.47 0.38 0.46   0.4 0.03 
(21:5n3) 0.40 0.39 0.38   0.4 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.45 0.47 0.59   0.5 0.04 
(22:5n6) 1.29 1.47 1.46   1.4 0.06 
DPA(22:5) 1.73 1.77 1.96   1.8 0.07 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 7.44 8.71 9.39   8.5 0.57 
Nervonic(24:1) 0.50 0.41 0.75   0.6 0.10 
Fatty Acid Indices 
Saturates 25.2 25.1 25.1   25.1 0.03 
Monoenes 34.8 32.2 34.3   33.8 0.81 
PUFA 40.0 42.7 40.6   41.1 0.81 
n6 10.3 11.0 10.4   10.6 0.21 
n3 28.8 30.6 29.2   29.5 0.57 
n3 HUFA 19.6 21.2 20.9   20.6 0.50 
n3/n6 2.8 2.8 2.8   2.8 0.00 
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Treatment: Cold Survivors 
Tissue: Muscle 
Fraction: Polar 
 
Name 
1=Run 
162 
2=Run 
199 
3=Run 
251   Mean SE 
              
Myristic(14:0) 1.89 0.95 1.01   1.3 0.30 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 16.86 15.56 15.78   16.1 0.40 
Palmitol(16:1) 2.40 1.41 1.37   1.7 0.34 
(16:2n4) 0.31 0.41 0.29   0.3 0.04 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.00 0.20 0.19   0.1 0.07 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 5.77 6.43 6.84   6.3 0.31 
Oleic(18:1) 8.49 6.08 6.24   6.9 0.78 
Vaccenic(18:1) 4.37 4.22 4.27   4.3 0.04 
Linoleic(18:2) 2.02 1.84 1.63   1.8 0.11 
gLinolen(18:3) 0.00 0.17 0.00   0.1 0.06 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 2.00 1.58 1.45   1.7 0.17 
Stearidon(18:4) 1.03 0.65 0.57   0.7 0.14 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.00 0.11 0.00   0.0 0.04 
Eicosen(20:1) 1.03 0.58 0.90   0.8 0.13 
Eicosad(20:2) 0.93 0.87 0.81   0.9 0.03 
(20:3n6) 0.32 0.35 0.34   0.3 0.01 
Arachidon(20:4) 6.23 6.91 6.33   6.5 0.21 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.21 1.10 1.22   1.2 0.04 
EPA(20:5) 6.14 6.62 5.88   6.2 0.22 
Behenic(22:0) 0.85 0.00 0.00   0.3 0.28 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.30 0.34 0.24   0.3 0.03 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.68 0.80 0.69   0.7 0.04 
(22:5n6) 3.20 3.80 3.59   3.5 0.17 
DPA(22:5) 2.55 2.74 2.61   2.6 0.06 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 31.43 36.30 37.74   35.2 1.91 
Nervonic(24:1) 0.00 0.00 0.00   0.0 0.00 
Fatty Acid Indices 
Saturates 25.4 23.0 23.6   24.0 0.70 
Monoenes 16.3 12.3 12.8   13.8 1.26 
PUFA 58.3 64.7 63.6   62.2 1.95 
n6 13.4 14.7 13.4   13.8 0.45 
n3 44.7 49.3 49.7   47.9 1.62 
n3 HUFA 41.6 47.1 47.7   45.5 1.93 
n3/n6 3.3 3.3 3.7   3.5 0.12 
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Treatment: Warm Survivors 
Tissue: Gill 
Fraction: Neutral 
 
Name 
1=Run 
171 
2=Run 
213 
3=Run 
267   Mean SE 
              
Myristic(14:0) 5.59 5.37 5.62   5.5 0.08 
Myristolic(14:1) 0.08 0.09 0.09   0.1 0.00 
Palmitic(16:0) 16.73 16.21 17.42   16.8 0.35 
Palmitol(16:1) 7.34 8.06 7.46   7.6 0.22 
(16:2n4) 0.66 0.50 0.61   0.6 0.05 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.35 0.36 0.40   0.4 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 2.40 2.21 2.58   2.4 0.11 
Oleic(18:1) 16.45 16.71 16.49   16.5 0.08 
Vaccenic(18:1) 4.22 4.43 4.26   4.3 0.06 
Linoleic(18:2) 4.67 4.58 4.41   4.6 0.08 
gLinolen(18:3) 0.39 0.09 0.10   0.2 0.10 
(18:3n4) 0.00 0.12 0.07   0.1 0.04 
aLinolen(18:3) 5.49 5.32 5.12   5.3 0.11 
Stearidon(18:4) 3.09 2.96 2.80   2.9 0.09 
(18:4n1) 0.00 0.13 0.08   0.1 0.04 
Arachidic(20:0) 0.52 0.46 0.48   0.5 0.02 
Eicosen(20:1) 1.67 2.09 1.95   1.9 0.12 
Eicosad(20:2) 1.10 1.23 1.08   1.1 0.05 
(20:3n6) 0.29 0.28 0.29   0.3 0.00 
Arachidon(20:4) 3.14 2.81 2.81   2.9 0.11 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.96 2.00 1.92   2.0 0.02 
EPA(20:5) 7.73 7.41 6.89   7.3 0.25 
Behenic(22:0) 0.31 0.17 0.13   0.2 0.06 
Erucic(22:1) 0.37 0.40 0.33   0.4 0.02 
(21:5n3) 0.35 0.38 0.34   0.4 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.76 0.79 0.73   0.8 0.02 
(22:5n6) 1.63 1.65 1.61   1.6 0.01 
DPA(22:5) 2.58 2.42 2.54   2.5 0.05 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 9.28 10.08 10.70   10.0 0.41 
Nervonic(24:1) 0.82 0.70 0.71   0.7 0.04 
Fatty Acid Indices 
Saturates 25.6 24.4 26.2   25.4 0.53 
Monoenes 31.0 32.5 31.3   31.6 0.46 
PUFA 43.5 43.1 42.5   43.0 0.29 
n6 12.0 11.4 11.0   11.5 0.28 
n3 30.5 30.6 30.3   30.5 0.08 
n3 HUFA 21.9 22.3 22.4   22.2 0.15 
n3/n6 2.5 2.7 2.7   2.7 0.06 
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Treatment: Warm Survivors 
Tissue: Gill 
Fraction: Polar 
 
Name 
1=Run 
172 
2=Run 
215 
3=Run 
257   Mean SE 
              
Myristic(14:0) 3.11 2.33 2.58   2.7 0.23 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 30.21 28.88 30.67   29.9 0.53 
Palmitol(16:1) 2.84 2.61 2.63   2.7 0.08 
(16:2n4) 1.23 1.16 1.03   1.1 0.06 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.45 0.41 0.41   0.4 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 10.35 10.05 10.44   10.3 0.12 
Oleic(18:1) 14.99 14.89 13.74   14.5 0.40 
Vaccenic(18:1) 3.69 3.68 3.93   3.8 0.08 
Linoleic(18:2) 1.06 1.17 1.08   1.1 0.03 
gLinolen(18:3) 0.38 0.36 0.21   0.3 0.05 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 0.61 0.79 0.73   0.7 0.05 
Stearidon(18:4) 0.22 0.26 0.31   0.3 0.02 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.63 0.71 0.42   0.6 0.09 
Eicosen(20:1) 0.59 0.44 0.59   0.5 0.05 
Eicosad(20:2) 0.43 0.54 0.45   0.5 0.03 
(20:3n6) 0.00 0.18 0.17   0.1 0.06 
Arachidon(20:4) 4.23 4.34 3.91   4.2 0.13 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.27 0.34 0.33   0.3 0.02 
EPA(20:5) 2.61 3.24 2.64   2.8 0.20 
Behenic(22:0) 0.00 0.00 0.00   0.0 0.00 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 1.43 0.00 0.00   0.5 0.48 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.14 1.34 1.13   1.2 0.07 
(22:5n6) 2.15 2.19 1.74   2.0 0.14 
DPA(22:5) 1.04 1.19 1.12   1.1 0.04 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 16.33 18.58 18.99   18.0 0.83 
Nervonic(24:1) 0.00 0.31 0.76   0.4 0.22 
Fatty Acid Indices 
Saturates 44.3 42.0 44.1   43.5 0.74 
Monoenes 22.1 21.9 21.6   21.9 0.14 
PUFA 33.6 36.1 34.3   34.6 0.75 
n6 9.4 10.1 8.7   9.4 0.41 
n3 22.5 24.4 24.1   23.7 0.58 
n3 HUFA 21.7 23.3 23.1   22.7 0.51 
n3/n6 2.4 2.4 2.8   2.57 0.12 
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Treatment: Warm Survivors 
Tissue: Liver 
Fraction: Neutral 
  
Name 
1=Run 
177 
2=Run 
228 
3=Run 
261   Mean SE 
              
Myristic(14:0) 4.11 4.24 4.51   4.3 0.12 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 20.37 19.38 21.34   20.4 0.57 
Palmitol(16:1) 6.89 7.21 7.10   7.1 0.09 
(16:2n4) 0.49 0.53 0.53   0.5 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.39 0.39 0.48   0.4 0.03 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 2.10 2.30 2.84   2.4 0.22 
Oleic(18:1) 13.08 14.15 14.21   13.8 0.37 
Vaccenic(18:1) 4.03 4.18 4.31   4.2 0.08 
Linoleic(18:2) 3.15 3.13 3.05   3.1 0.03 
gLinolen(18:3) 0.88 0.81 0.93   0.9 0.03 
(18:3n4) 0.00 0.14 0.08   0.1 0.04 
aLinolen(18:3) 2.83 2.56 2.69   2.7 0.08 
Stearidon(18:4) 3.28 2.93 3.22   3.1 0.11 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.11 0.11 0.11   0.1 0.00 
Eicosen(20:1) 0.96 0.23 0.19   0.5 0.25 
Eicosad(20:2) 0.76 0.78 0.69   0.7 0.03 
(20:3n6) 0.20 0.24 0.28   0.2 0.03 
Arachidon(20:4) 2.26 2.03 2.12   2.1 0.07 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.38 1.56 1.71   1.5 0.09 
EPA(20:5) 6.09 5.28 4.11   5.2 0.57 
Behenic(22:0) 0.00 0.00 0.00   0.0 0.00 
Erucic(22:1) 0.18 0.23 0.22   0.2 0.01 
(21:5n3) 0.42 0.42 0.47   0.4 0.02 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.10 1.30 1.40   1.3 0.09 
(22:5n6) 1.79 1.87 1.66   1.8 0.06 
DPA(22:5) 3.30 3.31 3.25   3.3 0.02 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 19.61 20.34 18.20   19.4 0.63 
Nervonic(24:1) 0.26 0.36 0.29   0.3 0.03 
Fatty Acid Indices 
Saturates 26.7 26.0 28.8   27.2 0.83 
Monoenes 25.4 26.4 26.3   26.0 0.32 
PUFA 47.9 47.6 44.9   46.8 0.96 
n6 10.1 10.1 10.1   10.1 0.01 
n3 36.9 36.4 33.7   35.7 1.01 
n3 HUFA 30.8 30.9 27.7   29.8 1.04 
n3/n6 3.6 3.6 3.3   3.5 0.10 
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Treatment: Warm Survivors 
Tissue: Liver 
Fraction: Polar 
 
Name 
1=Run 
192 
2=Run 
230 
3=Run 
262   Mean SE 
              
Myristic(14:0) 1.76 2.31 1.65   1.9 0.20 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 31.83 34.53 31.05   32.5 1.05 
Palmitol(16:1) 1.70 1.71 1.31   1.6 0.13 
(16:2n4) 0.37 0.36 0.34   0.4 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.14 0.17 0.16   0.2 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 7.53 7.79 11.69   9.0 1.35 
Oleic(18:1) 5.72 6.47 5.70   6.0 0.25 
Vaccenic(18:1) 2.11 2.13 1.85   2.0 0.09 
Linoleic(18:2) 0.69 0.70 0.56   0.6 0.04 
gLinolen(18:3) 0.00 0.11 0.13   0.1 0.04 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 0.49 0.44 0.00   0.3 0.16 
Stearidon(18:4) 0.41 0.34 0.26   0.3 0.04 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.00 0.11 0.09   0.1 0.04 
Eicosen(20:1) 0.30 0.40 0.27   0.3 0.04 
Eicosad(20:2) 0.63 0.71 0.57   0.6 0.04 
(20:3n6) 0.00 0.18 0.26   0.1 0.08 
Arachidon(20:4) 3.12 2.62 3.44   3.1 0.24 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.36 0.40 0.43   0.4 0.02 
EPA(20:5) 2.98 2.22 1.68   2.3 0.38 
Behenic(22:0) 0.00 0.00 1.26   0.4 0.42 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.00 0.00   0.0 0.00 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.90 0.82 0.74   0.8 0.05 
(22:5n6) 1.27 1.28 1.07   1.2 0.07 
DPA(22:5) 1.45 1.37 1.21   1.3 0.07 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 36.25 32.82 33.36   34.1 1.06 
Nervonic(24:1) 0.00 0.00 0.90   0.3 0.30 
Fatty Acid Indices 
Saturates 41.1 44.7 45.8   43.9 1.41 
Monoenes 9.8 10.7 10.0   10.2 0.27 
PUFA 49.1 44.6 44.2   45.9 1.56 
n6 6.6 6.4 6.8   6.6 0.10 
n3 41.9 37.6 36.9   38.8 1.57 
n3 HUFA 41.0 36.8 36.7   38.2 1.43 
n3/n6 6.3 5.8 5.5   5.9 0.26 
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Treatment: Warm Survivors 
Tissue: Muscle 
Fraction: Neutral 
 
Name 
1=Run 
173 
2=Run 
224 
3=Run 
258   Mean SE 
              
Myristic(14:0) 6.56 5.90 6.76   6.4 0.26 
Myristolic(14:1) 0.00 0.10 0.11   0.1 0.03 
Palmitic(16:0) 17.43 16.95 17.76   17.4 0.24 
Palmitol(16:1) 8.77 9.18 8.56   8.8 0.18 
(16:2n4) 0.39 0.42 0.42   0.4 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.52 0.36 0.36   0.4 0.05 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.82 1.95 2.04   1.9 0.06 
Oleic(18:1) 17.13 17.61 17.24   17.3 0.15 
Vaccenic(18:1) 4.30 4.41 4.16   4.3 0.07 
Linoleic(18:2) 4.66 4.68 4.71   4.7 0.01 
gLinolen(18:3) 0.38 0.07 0.08   0.2 0.10 
(18:3n4) 0.00 0.12 0.11   0.1 0.04 
aLinolen(18:3) 6.17 5.77 5.95   6.0 0.12 
Stearidon(18:4) 3.52 3.29 3.32   3.4 0.07 
(18:4n1) 0.00 0.06 0.00   0.0 0.02 
Arachidic(20:0) 0.28 0.30 0.32   0.3 0.01 
Eicosen(20:1) 1.64 0.41 0.39   0.8 0.41 
Eicosad(20:2) 1.13 1.27 1.16   1.2 0.04 
(20:3n6) 0.27 0.33 0.31   0.3 0.02 
Arachidon(20:4) 2.53 2.55 2.54   2.5 0.01 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.87 1.93 1.98   1.9 0.03 
EPA(20:5) 8.11 7.78 7.78   7.9 0.11 
Behenic(22:0) 0.14 0.15 0.17   0.2 0.01 
Erucic(22:1) 0.30 0.40 0.38   0.4 0.03 
(21:5n3) 0.35 0.40 0.39   0.4 0.02 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.45 0.59 0.48   0.5 0.04 
(22:5n6) 1.27 1.41 1.42   1.4 0.05 
DPA(22:5) 2.05 2.17 2.12   2.1 0.04 
Lignocer(24:0) 0.00 0.00 0.09   0.0 0.03 
DHA(22:6) 7.61 8.92 8.33   8.3 0.38 
Nervonic(24:1) 0.37 0.53 0.54   0.5 0.05 
Fatty Acid Indices 
Saturates 26.2 25.2 27.1   26.2 0.55 
Monoenes 32.5 32.7 31.4   32.2 0.40 
PUFA 41.3 42.1 41.5   41.6 0.25 
n6 10.7 10.9 10.7   10.8 0.07 
n3 29.7 30.3 29.9   29.9 0.17 
n3 HUFA 20.0 21.2 20.6   20.6 0.35 
n3/n6 2.8 2.8 2.8   2.8 0.01 
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Treatment: Warm Survivors 
Tissue: Muscle 
Fraction: Polar 
 
Name 
1=Run 
176 
2=Run 
227 
3=Run 
264   Mean SE 
              
Myristic(14:0) 1.11 1.08 0.07   0.8 0.34 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 29.71 29.03 28.23   29.0 0.43 
Palmitol(16:1) 1.40 1.42 1.09   1.3 0.11 
(16:2n4) 0.25 0.26 0.25   0.3 0.00 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.16 0.18 0.15   0.2 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 6.34 6.85 7.56   6.9 0.35 
Oleic(18:1) 6.92 7.30 6.12   6.8 0.35 
Vaccenic(18:1) 2.15 2.22 2.36   2.2 0.06 
Linoleic(18:2) 1.04 1.12 0.99   1.0 0.04 
gLinolen(18:3) 0.00 0.00 0.14   0.0 0.05 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 0.82 0.76 0.65   0.7 0.05 
Stearidon(18:4) 0.28 0.24 0.18   0.2 0.03 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.12 0.14 0.09   0.1 0.01 
Eicosen(20:1) 0.38 0.45 0.10   0.3 0.11 
Eicosad(20:2) 0.56 0.62 0.57   0.6 0.02 
(20:3n6) 0.14 0.16 0.15   0.2 0.01 
Arachidon(20:4) 6.35 6.70 6.21   6.4 0.15 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.42 0.43 0.42   0.4 0.01 
EPA(20:5) 7.87 7.81 6.15   7.3 0.56 
Behenic(22:0) 0.00 0.00 0.39   0.1 0.13 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.00 0.00   0.0 0.00 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.60 0.70 0.58   0.6 0.04 
(22:5n6) 2.47 2.70 2.46   2.5 0.08 
DPA(22:5) 1.55 1.58 1.71   1.6 0.05 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 29.36 28.25 33.18   30.3 1.49 
Nervonic(24:1) 0.00 0.00 0.22   0.1 0.07 
Fatty Acid Indices 
Saturates 37.3 37.1 36.3   36.9 0.29 
Monoenes 10.8 11.4 9.9   10.7 0.44 
PUFA 51.9 51.5 53.8   52.4 0.70 
n6 11.2 12.0 11.1   11.4 0.29 
n3 40.3 39.1 42.3   40.6 0.93 
n3 HUFA 39.2 38.1 41.4   39.6 0.99 
n3/n6 3.6 3.3 3.8   3.6 0.16 
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Treatment:  Cold Morts 
Tissue: Gill 
Fraction: Neutral 
 
Name 
1=Run 
281 
2=Run 
327 
3=Run 
349   Mean SE 
              
Myristic(14:0) 5.85 5.98 6.01   5.9 0.05 
Myristolic(14:1) 0.10 0.10 0.08   0.1 0.01 
Palmitic(16:0) 15.70 17.95 16.29   16.6 0.67 
Palmitol(16:1) 8.18 7.95 9.13   8.4 0.36 
(16:2n4) 0.55 0.56 0.53   0.5 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.43 0.48 0.40   0.4 0.02 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.99 2.12 1.82   2.0 0.09 
Oleic(18:1) 16.08 18.28 16.57   17.0 0.67 
Vaccenic(18:1) 4.41 4.69 4.62   4.6 0.08 
Linoleic(18:2) 4.65 4.73 4.89   4.8 0.07 
gLinolen(18:3) 0.42 0.09 0.08   0.2 0.11 
(18:3n4) 0.00 0.10 0.14   0.1 0.04 
aLinolen(18:3) 5.68 5.18 5.83   5.6 0.20 
Stearidon(18:4) 3.33 2.66 3.79   3.3 0.33 
(18:4n1) 0.18 0.21 0.15   0.2 0.02 
Arachidic(20:0) 0.35 0.48 0.35   0.4 0.04 
Eicosen(20:1) 1.83 2.13 0.45   1.5 0.52 
Eicosad(20:2) 1.18 1.18 1.34   1.2 0.05 
(20:3n6) 0.30 0.32 0.36   0.3 0.02 
Arachidon(20:4) 2.90 2.78 2.73   2.8 0.05 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 2.00 1.86 1.87   1.9 0.04 
EPA(20:5) 8.20 6.71 8.51   7.8 0.56 
Behenic(22:0) 0.11 0.16 0.13   0.1 0.01 
Erucic(22:1) 0.34 0.38 0.35   0.4 0.01 
(21:5n3) 0.39 0.32 0.43   0.4 0.03 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.68 0.71 0.65   0.7 0.02 
(22:5n6) 1.56 1.47 1.52   1.5 0.03 
DPA(22:5) 2.26 1.96 1.96   2.1 0.10 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 9.82 7.79 8.57   8.7 0.59 
Nervonic(24:1) 0.52 0.69 0.47   0.6 0.07 
Fatty Acid Indices 
Saturates 24.0 26.7 24.6   25.1 0.81 
Monoenes 31.5 34.2 31.7   32.5 0.89 
PUFA 44.5 39.1 43.7   42.5 1.70 
n6 11.7 11.3 11.6   11.5 0.12 
n3 31.7 26.5 31.0   29.7 1.63 
n3 HUFA 22.7 18.6 21.3   20.9 1.19 
n3/n6 2.7 2.3 2.7   2.6 0.12 
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Treatment: Cold Morts 
Tissue: Gill 
Fraction: Polar 
 
Name 
1=Run 
286 
2=Run 
319 
3=Run 
352   Mean SE 
              
Myristic(14:0) 3.13 2.12 2.34   2.5 0.31 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 27.80 22.48 26.19   25.5 1.58 
Palmitol(16:1) 2.63 1.91 2.46   2.3 0.22 
(16:2n4) 1.46 1.14 1.17   1.3 0.10 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.62 0.42 0.54   0.5 0.06 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 10.56 9.76 9.20   9.8 0.39 
Oleic(18:1) 10.72 10.20 10.04   10.3 0.20 
Vaccenic(18:1) 6.22 5.79 6.30   6.1 0.16 
Linoleic(18:2) 1.43 1.25 1.35   1.3 0.05 
gLinolen(18:3) 0.31 0.27 0.29   0.3 0.01 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 0.85 0.91 0.83   0.9 0.02 
Stearidon(18:4) 0.41 0.41 0.35   0.4 0.02 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.71 0.66 0.67   0.7 0.02 
Eicosen(20:1) 0.89 0.91 0.79   0.9 0.04 
Eicosad(20:2) 0.75 0.72 0.71   0.7 0.01 
(20:3n6) 0.00 0.24 0.24   0.2 0.08 
Arachidon(20:4) 5.41 5.96 5.94   5.8 0.18 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.50 0.59 0.45   0.5 0.04 
EPA(20:5) 3.57 4.19 4.20   4.0 0.21 
Behenic(22:0) 0.00 0.00 0.00   0.0 0.00 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.00 0.00   0.0 0.00 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.65 1.67 1.59   1.6 0.03 
(22:5n6) 2.51 3.16 2.52   2.7 0.21 
DPA(22:5) 1.30 1.61 1.30   1.4 0.10 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 16.58 23.18 19.99   19.9 1.90 
Nervonic(24:1) 0.00 0.48 0.54   0.3 0.17 
Fatty Acid Indices 
Saturates 42.2 35.0 38.4   38.5 2.08 
Monoenes 20.5 19.3 20.1   20.0 0.35 
PUFA 37.3 45.7 41.5   41.5 2.41 
n6 12.1 13.3 12.6   12.7 0.35 
n3 23.2 30.9 27.1   27.1 2.21 
n3 HUFA 22.0 29.6 25.9   25.8 2.20 
n3/n6 1.9 2.3 2.1   2.1 0.12 
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Treatment: Cold Morts 
Tissue: Liver  
Fraction: Neutral 
 
Name 
1=Run 
301 
2=Run 
332 
3=Run 
359   Mean SE 
              
Myristic(14:0) 5.44 5.45 4.96   5.3 0.16 
Myristolic(14:1) 0.09 0.10 0.00   0.1 0.03 
Palmitic(16:0) 12.12 12.53 12.69   12.4 0.17 
Palmitol(16:1) 7.60 7.42 8.34   7.8 0.28 
(16:2n4) 0.45 0.45 0.41   0.4 0.02 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.48 0.53 0.52   0.5 0.02 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.88 1.51 1.55   1.6 0.12 
Oleic(18:1) 22.78 24.64 20.86   22.8 1.09 
Vaccenic(18:1) 4.76 4.86 5.87   5.2 0.35 
Linoleic(18:2) 3.93 3.72 3.88   3.8 0.06 
gLinolen(18:3) 0.33 0.29 0.33   0.3 0.01 
(18:3n4) 0.00 0.07 0.00   0.0 0.02 
aLinolen(18:3) 4.64 4.32 4.43   4.5 0.09 
Stearidon(18:4) 2.70 2.53 3.05   2.8 0.16 
(18:4n1) 0.00 0.08 0.00   0.0 0.03 
Arachidic(20:0) 0.16 0.15 0.00   0.1 0.05 
Eicosen(20:1) 3.26 3.11 2.59   3.0 0.20 
Eicosad(20:2) 1.31 1.39 1.54   1.4 0.07 
(20:3n6) 0.27 0.30 0.24   0.3 0.02 
Arachidon(20:4) 2.38 2.02 2.50   2.3 0.15 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.62 1.67 1.87   1.7 0.08 
EPA(20:5) 6.08 5.61 6.51   6.1 0.26 
Behenic(22:0) 0.00 0.08 0.00   0.0 0.03 
Erucic(22:1) 0.69 0.74 0.65   0.7 0.03 
(21:5n3) 0.33 0.37 0.35   0.3 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.09 1.26 1.46   1.3 0.11 
(22:5n6) 1.80 1.76 1.74   1.8 0.02 
DPA(22:5) 2.20 2.19 1.86   2.1 0.11 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 10.66 9.88 10.74   10.4 0.28 
Nervonic(24:1) 0.95 1.01 1.06   1.0 0.03 
Fatty Acid Indices 
Saturates 19.6 19.7 19.2   19.5 0.16 
Monoenes 40.1 41.9 39.4   40.5 0.74 
PUFA 40.3 38.4 41.4   40.0 0.88 
n6 11.1 10.7 11.7   11.2 0.28 
n3 28.2 26.6 28.8   27.9 0.68 
n3 HUFA 20.9 19.7 21.3   20.6 0.48 
n3/n6 2.5 2.5 2.5   2.5 0.02 
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Treatment: Cold Morts 
Tissue: Liver 
Fraction: Polar 
 
Name 
1=Run 
302 
2=Run 
334 
3=Run 
358   Mean SE 
              
Myristic(14:0) 2.84 2.68 2.01   2.5 0.25 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 16.86 15.08 13.77   15.2 0.90 
Palmitol(16:1) 2.73 2.16 2.88   2.6 0.22 
(16:2n4) 0.60 0.56 0.68   0.6 0.04 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.26 0.20 0.28   0.2 0.02 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 3.95 3.69 3.51   3.7 0.13 
Oleic(18:1) 9.94 10.29 9.07   9.8 0.36 
Vaccenic(18:1) 5.88 6.42 6.29   6.2 0.16 
Linoleic(18:2) 1.57 1.26 1.73   1.5 0.14 
gLinolen(18:3) 0.00 0.10 0.00   0.0 0.03 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 1.39 1.10 1.65   1.4 0.16 
Stearidon(18:4) 0.69 0.50 0.84   0.7 0.10 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.20 0.19 0.22   0.2 0.01 
Eicosen(20:1) 2.51 2.85 2.05   2.5 0.23 
Eicosad(20:2) 2.37 2.31 2.59   2.4 0.09 
(20:3n6) 0.43 0.38 0.47   0.4 0.02 
Arachidon(20:4) 3.18 3.15 3.54   3.3 0.12 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.06 1.22 1.41   1.2 0.10 
EPA(20:5) 3.24 2.54 3.82   3.2 0.37 
Behenic(22:0) 0.74 0.00 0.00   0.2 0.25 
Erucic(22:1) 0.00 0.20 0.00   0.1 0.07 
(21:5n3) 0.00 0.13 0.00   0.0 0.04 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 1.20 1.11 1.93   1.4 0.26 
(22:5n6) 2.86 2.96 2.58   2.8 0.11 
DPA(22:5) 2.64 2.85 2.47   2.7 0.11 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 32.46 35.55 35.67   34.6 1.05 
Nervonic(24:1) 0.40 0.48 0.55   0.5 0.04 
Fatty Acid Indices 
Saturates 24.6 21.6 19.5   21.9 1.48 
Monoenes 21.4 22.4 20.8   21.6 0.46 
PUFA 54.0 56.0 59.7   56.5 1.68 
n6 11.6 11.3 12.8   11.9 0.47 
n3 41.5 43.9 45.9   43.8 1.27 
n3 HUFA 39.4 42.3 43.4   41.7 1.19 
n3/n6 3.6 3.9 3.6   3.7 0.11 
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Treatment: Cold Morts 
Tissue: Muscle 
Fraction: Neutral 
 
Name 
1=Run 
303 
2=Run 
322 
3=Run 
353   Mean SE 
              
Myristic(14:0) 6.03 5.83 6.08   6.0 0.08 
Myristolic(14:1) 0.09 0.10 0.00   0.1 0.03 
Palmitic(16:0) 16.53 17.67 17.24   17.1 0.33 
Palmitol(16:1) 8.23 7.86 9.12   8.4 0.37 
(16:2n4) 0.40 0.44 0.40   0.4 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.35 0.38 0.40   0.4 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.85 1.94 1.50   1.8 0.13 
Oleic(18:1) 18.70 19.59 16.66   18.3 0.87 
Vaccenic(18:1) 4.14 4.23 4.76   4.4 0.20 
Linoleic(18:2) 4.44 4.42 4.51   4.5 0.03 
gLinolen(18:3) 0.38 0.07 0.41   0.3 0.11 
(18:3n4) 0.09 0.11 0.00   0.1 0.03 
aLinolen(18:3) 5.76 5.56 5.35   5.6 0.12 
Stearidon(18:4) 3.52 3.50 3.92   3.6 0.14 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.26 0.29 0.23   0.3 0.02 
Eicosen(20:1) 2.39 0.36 1.94   1.6 0.62 
Eicosad(20:2) 1.18 1.19 1.37   1.2 0.06 
(20:3n6) 0.26 0.30 0.29   0.3 0.01 
Arachidon(20:4) 2.38 2.48 2.37   2.4 0.03 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.96 2.00 1.84   1.9 0.05 
EPA(20:5) 7.63 8.02 8.07   7.9 0.14 
Behenic(22:0) 0.11 0.14 0.00   0.1 0.04 
Erucic(22:1) 0.40 0.45 0.37   0.4 0.03 
(21:5n3) 0.38 0.41 0.41   0.4 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.45 0.47 0.44   0.5 0.01 
(22:5n6) 1.38 1.45 1.44   1.4 0.02 
DPA(22:5) 1.92 1.93 1.66   1.8 0.09 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 8.33 8.30 8.79   8.5 0.16 
Nervonic(24:1) 0.45 0.52 0.43   0.5 0.03 
Fatty Acid Indices 
Saturates 24.8 25.9 25.0   25.2 0.33 
Monoenes 34.4 33.1 33.3   33.6 0.41 
PUFA 40.8 41.0 41.7   41.2 0.26 
n6 10.5 10.4 10.8   10.6 0.14 
n3 29.5 29.7 30.0   29.8 0.16 
n3 HUFA 20.2 20.7 20.8   20.6 0.17 
n3/n6 2.8 2.9 2.8   2.8 0.03 
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Treatment: Cold Morts 
Tissue: Muscle 
Fraction: Polar 
 
Name 
1=Run 
300 
2=Run 
326 
3=Run 
392   Mean SE 
              
Myristic(14:0) 0.89 1.31 0.96   1.1 0.13 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 19.31 23.22 20.41   21.0 1.17 
Palmitol(16:1) 1.13 1.46 1.24   1.3 0.10 
(16:2n4) 0.29 0.24 0.30   0.3 0.02 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.17 0.00 0.18   0.1 0.06 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 6.04 6.95 5.74   6.2 0.36 
Oleic(18:1) 5.07 5.70 5.17   5.3 0.20 
Vaccenic(18:1) 3.56 3.75 3.66   3.7 0.05 
Linoleic(18:2) 1.43 1.50 1.69   1.5 0.08 
gLinolen(18:3) 0.10 0.19 0.00   0.1 0.05 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 1.23 1.18 1.24   1.2 0.02 
Stearidon(18:4) 0.49 0.49 0.52   0.5 0.01 
(18:4n1) 0.00 0.16 0.00   0.1 0.05 
Arachidic(20:0) 0.08 0.21 0.00   0.1 0.06 
Eicosen(20:1) 0.50 0.77 0.42   0.6 0.10 
Eicosad(20:2) 0.72 0.81 0.72   0.7 0.03 
(20:3n6) 0.26 0.37 0.30   0.3 0.03 
Arachidon(20:4) 6.45 6.41 6.13   6.3 0.10 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.93 0.91 0.95   0.9 0.01 
EPA(20:5) 6.97 5.99 6.38   6.4 0.29 
Behenic(22:0) 0.00 0.00 0.00   0.0 0.00 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.29 0.26 0.69   0.4 0.14 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.56 0.52 0.74   0.6 0.07 
(22:5n6) 3.45 3.21 3.63   3.4 0.12 
DPA(22:5) 2.47 2.19 2.47   2.4 0.09 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 37.60 32.21 36.46   35.4 1.64 
Nervonic(24:1) 0.00 0.00 0.00   0.0 0.00 
Fatty Acid Indices 
Saturates 26.3 31.7 27.1   28.4 1.67 
Monoenes 10.3 11.7 10.5   10.8 0.44 
PUFA 63.4 56.6 62.4   60.8 2.11 
n6 13.0 13.0 13.2   13.1 0.08 
n3 50.0 43.2 48.7   47.3 2.07 
n3 HUFA 48.3 41.6 46.9   45.6 2.05 
n3/n6 3.9 3.3 3.7   3.6 0.16 
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Treatment: Warm Morts 
Tissue: Gill 
Fraction: Neutral 
 
Name 
1=Run 
305 
2=Run 
338 
3=Run 
361   Mean SE 
              
Myristic(14:0) 5.73 5.89 5.46   5.7 0.13 
Myristolic(14:1) 0.10 0.12 0.12   0.1 0.01 
Palmitic(16:0) 16.60 16.44 16.53   16.5 0.05 
Palmitol(16:1) 7.90 8.19 7.58   7.9 0.18 
(16:2n4) 0.52 0.40 0.59   0.5 0.06 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.53 0.66 0.57   0.6 0.04 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.81 2.38 1.92   2.0 0.18 
Oleic(18:1) 17.86 15.57 19.32   17.6 1.09 
Vaccenic(18:1) 4.36 3.71 4.05   4.0 0.19 
Linoleic(18:2) 4.39 4.87 4.40   4.6 0.16 
gLinolen(18:3) 0.08 0.10 0.08   0.1 0.00 
(18:3n4) 0.11 0.11 0.09   0.1 0.01 
aLinolen(18:3) 5.35 6.56 5.28   5.7 0.42 
Stearidon(18:4) 2.95 3.48 2.95   3.1 0.18 
(18:4n1) 0.06 0.35 0.39   0.3 0.10 
Arachidic(20:0) 0.42 0.44 0.48   0.4 0.02 
Eicosen(20:1) 1.84 0.36 2.21   1.5 0.56 
Eicosad(20:2) 1.02 1.02 1.00   1.0 0.01 
(20:3n6) 0.31 0.28 0.30   0.3 0.01 
Arachidon(20:4) 2.82 3.13 2.71   2.9 0.13 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 2.03 1.79 2.08   2.0 0.09 
EPA(20:5) 6.75 8.42 6.76   7.3 0.55 
Behenic(22:0) 0.13 0.16 0.17   0.2 0.01 
Erucic(22:1) 0.34 0.27 0.38   0.3 0.03 
(21:5n3) 0.35 0.37 0.35   0.4 0.01 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.64 0.69 0.64   0.7 0.02 
(22:5n6) 1.56 1.53 1.42   1.5 0.04 
DPA(22:5) 2.44 2.43 2.38   2.4 0.02 
Lignocer(24:0) 0.00 0.10 0.00   0.0 0.03 
DHA(22:6) 10.31 9.58 9.03   9.6 0.37 
Nervonic(24:1) 0.66 0.60 0.75   0.7 0.04 
Fatty Acid Indices 
Saturates 24.7 25.4 24.6   24.9 0.26 
Monoenes 33.1 28.8 34.4   32.1 1.68 
PUFA 42.2 45.8 41.0   43.0 1.42 
n6 10.8 11.6 10.6   11.0 0.32 
n3 30.2 32.6 28.8   30.6 1.12 
n3 HUFA 21.9 22.6 20.6   21.7 0.59 
n3/n6 2.8 2.8 2.7   2.8 0.02 
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Treatment: Warm Morts 
Tissue: Gill 
Fraction: Polar 
 
Name 
1=Run 
307 
2=Run 
342 
3=Run 
362   Mean SE 
              
Myristic(14:0) 3.83 3.51 3.83   3.7 0.11 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 32.33 30.40 36.82   33.2 1.90 
Palmitol(16:1) 3.09 3.09 2.71   3.0 0.13 
(16:2n4) 0.97 1.23 0.82   1.0 0.12 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.67 0.51 0.94   0.7 0.12 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 12.00 10.42 9.80   10.7 0.66 
Oleic(18:1) 12.74 15.59 15.01   14.4 0.87 
Vaccenic(18:1) 3.29 3.79 3.82   3.6 0.17 
Linoleic(18:2) 1.11 1.16 0.85   1.0 0.10 
gLinolen(18:3) 0.42 0.41 0.37   0.4 0.02 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 0.79 0.72 0.55   0.7 0.07 
Stearidon(18:4) 0.30 0.23 0.00   0.2 0.09 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 1.11 0.88 0.96   1.0 0.07 
Eicosen(20:1) 0.98 0.81 0.82   0.9 0.05 
Eicosad(20:2) 0.49 0.53 0.43   0.5 0.03 
(20:3n6) 0.00 0.16 0.79   0.3 0.24 
Arachidon(20:4) 3.82 4.33 3.35   3.8 0.28 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.40 0.28 0.25   0.3 0.04 
EPA(20:5) 2.45 2.53 2.15   2.4 0.12 
Behenic(22:0) 0.33 0.15 0.67   0.4 0.15 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.00 0.00   0.0 0.00 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 2.05 1.22 1.00   1.4 0.32 
(22:5n6) 1.80 2.20 1.52   1.8 0.19 
DPA(22:5) 0.86 1.07 0.74   0.9 0.10 
Lignocer(24:0) 1.06 0.55 0.69   0.8 0.15 
DHA(22:6) 11.98 13.78 10.39   12.0 0.98 
Nervonic(24:1) 1.14 0.45 0.72   0.8 0.20 
Fatty Acid Indices 
Saturates 50.7 45.9 52.8   49.8 2.03 
Monoenes 21.2 23.7 23.1   22.7 0.75 
PUFA 28.1 30.4 24.2   27.5 1.81 
n6 9.7 10.0 8.3   9.3 0.52 
n3 16.8 18.6 14.1   16.5 1.32 
n3 HUFA 15.7 17.7 13.5   15.6 1.19 
n3/n6 1.7 1.9 1.7   1.8 0.05 
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Treatment: Warm Morts 
Tissue: Liver 
Fraction: Neutral 
 
Name 
1=Run 
311 
2=Run 
348 
3=Run 
375   Mean SE 
              
Myristic(14:0) 5.50 5.53 5.36   5.5 0.05 
Myristolic(14:1) 0.07 0.07 0.07   0.1 0.00 
Palmitic(16:0) 19.82 22.76 18.27   20.3 1.32 
Palmitol(16:1) 7.84 7.35 7.10   7.4 0.22 
(16:2n4) 0.47 0.45 0.51   0.5 0.02 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.44 0.35 0.56   0.5 0.06 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 2.31 3.02 2.44   2.6 0.22 
Oleic(18:1) 18.19 13.89 22.36   18.1 2.45 
Vaccenic(18:1) 4.43 4.18 3.96   4.2 0.14 
Linoleic(18:2) 3.61 3.68 3.39   3.6 0.09 
gLinolen(18:3) 0.05 0.08 0.60   0.2 0.18 
(18:3n4) 0.10 0.05 0.08   0.1 0.01 
aLinolen(18:3) 3.93 4.14 3.45   3.8 0.21 
Stearidon(18:4) 2.99 3.00 2.68   2.9 0.11 
(18:4n1) 0.08 0.06 0.00   0.0 0.02 
Arachidic(20:0) 0.18 0.27 0.16   0.2 0.03 
Eicosen(20:1) 0.27 0.28 0.24   0.3 0.01 
Eicosad(20:2) 0.94 0.88 0.79   0.9 0.04 
(20:3n6) 0.25 0.19 0.30   0.2 0.03 
Arachidon(20:4) 1.98 2.39 1.86   2.1 0.16 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.57 1.26 1.76   1.5 0.15 
EPA(20:5) 5.15 6.01 4.24   5.1 0.51 
Behenic(22:0) 0.08 0.09 0.09   0.1 0.01 
Erucic(22:1) 0.31 0.25 0.43   0.3 0.05 
(21:5n3) 0.37 0.32 0.40   0.4 0.02 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.92 0.83 1.29   1.0 0.14 
(22:5n6) 1.65 1.58 1.52   1.6 0.04 
DPA(22:5) 2.31 0.00 2.62   1.6 0.83 
Lignocer(24:0) 0.00 2.29 0.00   0.8 0.76 
DHA(22:6) 13.75 14.25 12.76   13.6 0.44 
Nervonic(24:1) 0.46 0.51 0.69   0.6 0.07 
Fatty Acid Indices 
Saturates 27.9 34.0 26.3   29.4 2.33 
Monoenes 31.6 26.5 34.9   31.0 2.42 
PUFA 40.5 39.5 38.8   39.6 0.50 
n6 9.4 9.6 9.8   9.6 0.10 
n3 30.1 29.0 27.9   29.0 0.62 
n3 HUFA 23.1 21.8 21.8   22.3 0.44 
n3/n6 3.2 3.0 2.9   3.0 0.10 
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Treatment: Warm Morts 
Tissue: Liver 
Fraction: Polar 
 
Name 
1=Run 
316 
2=Run 
347 
3=Run 
377   Mean SE 
              
Myristic(14:0) 4.21 2.87 4.16   3.7 0.44 
Myristolic(14:1) 0.00 0.00 0.06   0.0 0.02 
Palmitic(16:0) 30.02 35.86 34.39   33.4 1.75 
Palmitol(16:1) 2.72 2.07 2.09   2.3 0.21 
(16:2n4) 0.40 0.36 0.39   0.4 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.23 0.19 0.20   0.2 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 9.14 12.09 9.29   10.2 0.96 
Oleic(18:1) 7.63 5.85 7.66   7.0 0.60 
Vaccenic(18:1) 2.71 2.61 2.23   2.5 0.15 
Linoleic(18:2) 1.11 0.84 0.86   0.9 0.09 
gLinolen(18:3) 0.00 0.22 0.11   0.1 0.06 
(18:3n4) 0.00 0.00 0.05   0.0 0.02 
aLinolen(18:3) 1.05 0.65 0.76   0.8 0.12 
Stearidon(18:4) 0.74 0.42 0.48   0.5 0.10 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.00 0.24 0.16   0.1 0.07 
Eicosen(20:1) 0.76 0.53 0.10   0.5 0.19 
Eicosad(20:2) 0.73 0.82 0.66   0.7 0.05 
(20:3n6) 0.23 0.00 0.29   0.2 0.09 
Arachidon(20:4) 5.35 4.36 4.36   4.7 0.33 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.57 0.31 0.49   0.5 0.07 
EPA(20:5) 2.42 1.86 1.76   2.0 0.21 
Behenic(22:0) 0.00 0.00 0.10   0.0 0.03 
Erucic(22:1) 0.00 0.00 0.13   0.0 0.04 
(21:5n3) 0.00 0.00 0.06   0.0 0.02 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.67 0.61 0.56   0.6 0.03 
(22:5n6) 1.35 1.46 1.22   1.3 0.07 
DPA(22:5) 1.37 1.33 1.52   1.4 0.06 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 26.59 24.46 25.56   25.5 0.62 
Nervonic(24:1) 0.00 0.00 0.29   0.1 0.10 
Fatty Acid Indices 
Saturates 43.4 51.1 48.1   47.5 2.24 
Monoenes 13.8 11.1 12.6   12.5 0.80 
PUFA 42.8 37.9 39.3   40.0 1.46 
n6 9.4 8.3 8.1   8.6 0.43 
n3 32.7 29.0 30.6   30.8 1.07 
n3 HUFA 30.9 28.0 29.4   29.4 0.86 
n3/n6 3.5 3.5 3.8   3.6 0.11 
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Treatment: Warm Morts 
Tissue: Muscle 
Fraction: Neutral 
 
Name 
1=Run 
328 
2=Run 
343 
3=Run 
371   Mean SE 
              
Myristic(14:0) 6.07 6.23 5.78   6.0 0.13 
Myristolic(14:1) 0.11 0.12 0.13   0.1 0.01 
Palmitic(16:0) 17.03 15.93 16.72   16.6 0.33 
Palmitol(16:1) 8.01 8.86 7.72   8.2 0.34 
(16:2n4) 0.42 0.45 0.43   0.4 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.41 0.74 0.43   0.5 0.11 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 1.89 2.39 2.07   2.1 0.15 
Oleic(18:1) 19.67 16.74 20.78   19.1 1.20 
Vaccenic(18:1) 4.25 3.75 3.80   3.9 0.16 
Linoleic(18:2) 4.65 5.14 4.78   4.9 0.15 
gLinolen(18:3) 0.08 0.08 0.07   0.1 0.00 
(18:3n4) 0.10 0.10 0.09   0.1 0.00 
aLinolen(18:3) 5.90 7.86 6.03   6.6 0.63 
Stearidon(18:4) 3.13 3.98 3.44   3.5 0.25 
(18:4n1) 0.00 0.05 0.00   0.0 0.02 
Arachidic(20:0) 0.31 0.33 0.31   0.3 0.01 
Eicosen(20:1) 2.17 0.28 0.30   0.9 0.63 
Eicosad(20:2) 1.04 0.96 0.96   1.0 0.03 
(20:3n6) 0.31 0.29 0.31   0.3 0.01 
Arachidon(20:4) 2.46 2.74 2.80   2.7 0.10 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 1.90 1.83 2.05   1.9 0.06 
EPA(20:5) 6.73 8.09 7.51   7.4 0.39 
Behenic(22:0) 0.16 0.18 0.16   0.2 0.01 
Erucic(22:1) 0.40 0.33 0.41   0.4 0.02 
(21:5n3) 0.35 0.40 0.40   0.4 0.02 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.48 0.48 0.53   0.5 0.02 
(22:5n6) 1.38 1.27 1.02   1.2 0.11 
DPA(22:5) 2.08 2.31 2.19   2.2 0.07 
Lignocer(24:0) 0.00 0.10 0.00   0.0 0.03 
DHA(22:6) 7.96 7.56 8.19   7.9 0.18 
Nervonic(24:1) 0.55 0.43 0.59   0.5 0.05 
Fatty Acid Indices 
Saturates 25.5 25.2 25.0   25.2 0.12 
Monoenes 35.2 30.5 33.7   33.1 1.37 
PUFA 39.4 44.3 41.2   41.7 1.44 
n6 10.4 11.0 10.5   10.6 0.18 
n3 28.1 32.0 29.8   30.0 1.15 
n3 HUFA 19.0 20.2 20.3   19.9 0.42 
n3/n6 2.7 2.9 2.8   2.8 0.07 
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Treatment: Warm Morts  
Tissue: Muscle 
Fraction: Polar 
 
Name 
1=Run 
310 
2=Run 
344 
3=Run 
373   Mean SE 
              
Myristic(14:0) 1.09 1.16 1.19   1.1 0.03 
Myristolic(14:1) 0.00 0.00 0.00   0.0 0.00 
Palmitic(16:0) 28.08 28.74 29.93   28.9 0.54 
Palmitol(16:1) 1.22 1.50 1.42   1.4 0.08 
(16:2n4) 0.21 0.25 0.22   0.2 0.01 
(17:0) N/A N/A N/A   N/A N/A 
(16:3n4) 0.17 0.16 0.18   0.2 0.01 
(16:4n1) N/A N/A N/A   N/A N/A 
Stearic(18:0) 6.45 6.71 6.32   6.5 0.11 
Oleic(18:1) 6.63 6.85 8.06   7.2 0.44 
Vaccenic(18:1) 2.09 2.12 2.31   2.2 0.07 
Linoleic(18:2) 0.99 1.12 1.16   1.1 0.05 
gLinolen(18:3) 0.12 0.14 0.00   0.1 0.04 
(18:3n4) 0.00 0.00 0.00   0.0 0.00 
aLinolen(18:3) 0.67 0.95 0.83   0.8 0.08 
Stearidon(18:4) 0.25 0.33 0.34   0.3 0.03 
(18:4n1) 0.00 0.00 0.00   0.0 0.00 
Arachidic(20:0) 0.10 0.14 0.00   0.1 0.04 
Eicosen(20:1) 0.11 0.41 0.52   0.3 0.12 
Eicosad(20:2) 0.52 0.56 0.61   0.6 0.02 
(20:3n6) 0.19 0.19 0.20   0.2 0.00 
Arachidon(20:4) 6.58 6.64 5.88   6.4 0.24 
Eicosatri(20:3) N/A N/A N/A   N/A N/A 
(20:4n3) 0.44 0.39 0.51   0.4 0.03 
EPA(20:5) 7.16 8.08 6.86   7.4 0.37 
Behenic(22:0) 0.00 0.80 0.00   0.3 0.27 
Erucic(22:1) 0.00 0.00 0.00   0.0 0.00 
(21:5n3) 0.00 0.00 0.00   0.0 0.00 
Tricosa(23:0) N/A N/A N/A   N/A N/A 
Docosatet(22:4) 0.62 0.52 0.64   0.6 0.04 
(22:5n6) 2.61 2.38 2.61   2.5 0.08 
DPA(22:5) 1.52 1.50 1.52   1.5 0.01 
Lignocer(24:0) 0.00 0.00 0.00   0.0 0.00 
DHA(22:6) 32.19 28.36 28.68   29.7 1.23 
Nervonic(24:1) 0.00 0.00 0.00   0.0 0.00 
Fatty Acid Indices 
Saturates 35.7 37.5 37.4   36.9 0.59 
Monoenes 10.1 10.9 12.3   11.1 0.66 
PUFA 54.2 51.6 50.2   52.0 1.17 
n6 11.6 11.5 11.1   11.4 0.17 
n3 42.2 39.6 38.7   40.2 1.04 
n3 HUFA 41.3 38.3 37.6   39.1 1.14 
n3/n6 3.6 3.4 3.5   3.5 0.06 
 
